

16. mednarodni simpozij
(16th International Symposium)

**USPEŠEN ZDRAVSTVENI SISTEM IN
PODOBNA BIOLOŠKA ZDRAVILA: ALI
OBSTAJA POVEZAVA?**

***HEALTH SYSTEMS CAN'T AFFORD NOT TO HAVE
BIOSIMILARS: HOW TO MAKE THEM A SUCCESS?***

Zbornik povzetkov in izročkov
(Book of abstracts and handouts)

Strokovno-organizacijski odbor simpozija:

dr. Aljaž Sočan – predsednik SBF

Vesna Bizjak

mag. Franci Tratar

Simona Mitrović

Bernarda Emeršič

Marijana Fortuna Lužar

Danila Hriberšek

Anja Soukup

Tajda Miharija Gala

KOLOFON

e-zbornik povzetkov predavanj in izročkov 16. mednarodnega simpozija Sekcije bolnišničnih farmacevtov pri SFD:

USPEŠEN ZDRAVSTVENI SISTEM IN PODOBNA BIOLOŠKA ZDRAVILA: ALI OBSTAJA POVEZAVA?

Dostop: www.sfd.si

Zbrala: Bernarda Emeršič, mag. farm., spec.

Uredil: mag. Franci Tratar, mag. farm., spec.

Založnik

Slovensko farmacevtsko društvo, Sekcija bolnišničnih farmacevtov

Dunajska 184A, SI – 1000 Ljubljana, Slovenija

Tel.: +386 1 569 26 01

Fax: +386 1 569 26 02

e-naslov: info@sfd.si,

www.sfd.si

Kataložni zapis o publikaciji (CIP) pripravili v Narodni in univerzitetni knjižnici v Ljubljani

COBISS.SI-ID 213827075

ISBN 978-961-94230-6-6 (PDF)

Ljubljana, 5. november 2024

Kazalo vsebine

Predstavitev predavateljev.....	3
Speaker Introductions	3
Povzetki in izročki predavanj	14
Lecture Abstracts and Handouts	14
Podobna biološka zdravila: kaj so in kako jih razvijajo?	15
Biosimilars: what are they, how are they developed?	15
Podobna biološka zdravila: Zakaj so dobra za nas?.....	23
Biosimilars: why are they good for us?	23
Podobna biološka zdravila: Kateri so ključni dejavniki za uspeh?	29
Biosimilars: What are the key factors for success? The European Landscape.....	29
Podobna biološka zdravila: ekstrapolacija indikacij namesto kliničnih raziskav	34
Biosimilars: extrapolation of indications instead of clinical trial.....	34
Podobna biološka zdravila: izkušnje s področja hematologije	41
Biosimilars: Experiences in Hematology	41
Podobna biološka zdravila: izkušnje s področja gastroenterologije in zdravljenja kronične vnetne črevesne bolezni	47
Biosimilars: Experiences in Gastroenterology and the Treatment of Chronic Inflammatory Bowel Disease	47
Podobna biološka zdravila: izkušnje s področja onkologije	56
Biosimilars: Experience in Oncology.....	56
Podobna biološka zdravila: izkušnje s področja revmatologije.....	65
Biosimilars: Experiences in Rheumatology.....	65
5 pravil za uspešno uvedbo podobnih bioloških zdravil.....	77
The 5 rules for successful introduction of biosimilars.....	77
Izkušnje bolnišničnega farmacevta z implementacijo podobnih bioloških zdravil v klinični praksi	85
The experience of a hospital pharmacist with the implementation of biosimilars in clinical practice	85
Vloga medicinske sestre pri implementaciji podobnih bioloških zdravil	91
The role of the nurse in the implementation of biosimilars	91
Ali bomo v prihodnosti imeli na voljo podobna biološka zdravila?.....	101
Will we have biosimilars in the future? The biosimilar Void.....	101
Vzdržnost zdravstvenega sistema in uspešna implementacija podobnih bioloških zdravil v Sloveniji: Kako doseči oboje?	106
How to make biosimilars a sustainable success in Slovenia.....	106

Predstavitev predavateljev

Speaker Introductions

Arnold G. Vulto

Elektronska pošta / e-mail: a.vulto@gmail.com

Ustanova / Institution: Erasmus University Medical Center, Dept. Of Hospital Pharmacy, Rotterdam, The Netherlands

Kratka predstavitev / Short introduction:

Arnold G. Vulto je mednarodno priznan strokovnjak na področju bioloških zdravil, zlasti podobnih bioloških zdravil. Preko svojega podjetja VuPEC (www.vupec.com) izobražuje in svetuje farmacevtskim podjetjem, vladam, regulativnim organom in drugim organizacijam o trgu podobnih bioloških zdravil in politiki na tem področju. Pogosto je vabljen kot govornik na konferencah in izobraževalnih dogodkih o podobnih bioloških zdravilih po vsem svetu.

Profesor Vulto je (so)avtor več kot 230 mednarodnih strokovno pregledanih člankov (povezava: <https://pure.eur.nl/en/persons/arnold-vulto>) ter je doslej nadzoroval skupno 50 specializantov bolnišnične farmacije in doktorskih študentov. Bil je član Upravnega odbora EAHP in predsednik Znanstvenega odbora (2004-2008). Bil je član usmerjevalnega odbora in predsednik programskega odbora Prve globalne konference o prihodnosti bolnišnične farmacije (Basel, 2008). Leta 2010 je bil prof. Vulto izvoljen za člana Ameriškega kolegija klinične farmakologije (FCP). Prejel je različne nagrade, med njimi nagrado za »vizionarsko vodstvo in usmeritev« v bolnišnični farmaciji (EAHP) in nagrado Jana Gleruma za življenjsko delo zaradi prispevka k usposabljanju bolnišničnih farmacevtov. Leta 2019 je bil izvoljen za častnega člana Združenja bolnišničnih farmacevtov na Nizozemskem. Profesor Vulto je bil 8 let glavni urednik European Journal of Hospital Pharmacy Practice (2004-2012).

Profesor Vulto je eden od soustanoviteljev iniciative za generična in podobna biološka zdravila (GaBI; 2008) ter iniciativne skupine za podobna biološka zdravila na Nizozemskem (2013). Leta 2015 je bil pobudnik in voditelj Prve nacionalne konference o podobnih bioloških zdravilih na Nizozemskem. Leta 2016 je bil eden od ustanoviteljev raziskovalnega sklada MABEL na Univerzi v Leuvenu v Belgiji.

Arnold G. Vulto is an internationally renowned expert in biological medicines, especially biosimilars. Through his company VuPEC (www.vupec.com) he educates and advises pharmaceutical companies, governments, regulatory bodies, and other organizations on the market for biosimilars and biosimilars policy. He is a frequently invited speaker at biosimilars conferences / educational events all over the world.

Professor Vulto is the (co)author of more than 230 international peer reviewed papers (link: <https://pure.eur.nl/en/persons/arnold-vulto>) and has been supervising in total 50 hospital pharmacy residents and PhD students. He was member of the Board of Directors of the EAHP and was Chairman of its Scientific Committee (2004-2008). He was a member of the Steering Committee and chair of the Program Committee of the First Global Conference on the Future of Hospital Pharmacy (Basel, 2008). In 2010 Prof. Vulto was elected as Fellow of the American College of Clinical

Pharmacology (FCP). He received different awards: “Visionary guidance and leadership” in hospital pharmacy (EAHP) and the Jan Glerum Lifetime Achievement Award for his contribution to the training of hospital pharmacists. In 2019 he was elected as a lifetime Honorary Member of the Dutch Society of Hospital Pharmacists. Professor Vulto was for 8 years Editor in Chief of the European Journal of Hospital Pharmacy Practice (2004-2012).

Professor Vulto is one of the co-founders of the Generics & Biosimilars Initiative (GaBI; 2008) and the Initiative Group Biosimilars The Netherlands (2013). In 2015 he initiated and chaired the First National Conference on Biosimilars in The Netherlands. In 2016 he was one of the founders of the MABEL Research Fund at Leuven University, Belgium.

Aurelio Arias

Elektronska pošta/*e-mail*:

Ustanova / *Institution*: IQVIA

Kratka predstavitev / *Short introduction*:

Aurelio ustvarja strateške vsebine, ki so aktualne in usmerjene v prihodnost ter relevantne za globalne vodstvene kadre v farmaciji, pri čemer redno objavlja članke, bloge in bele knjige. Njegovo delo je osredotočeno na trge po izteku patentne zaščite, kjer z raziskavami, ki temeljijo na dokazih, spodbuja razprave o različnih temah, pomembnih za farmacevtsko industrijo. Velja za strokovnjaka na več področjih, vključno s podobnimi biološkimi zdravili, digitalnim zdravjem in ESG (okoljsko, družbeno in korporativno upravljanje), redno sodeluje na konferencah po svetu, predstavlja na sestankih upravnih odborov ter sodeluje pri svetovalnih projektih.

Aurelio creates topical and forward-looking strategic content relevant to global pharma executives and publishes articles, blogs, and white papers on a regular basis.

Aurelio focuses on off-patent markets where he generates evidence-led insights with a view to spark high-level discourse on various topics relevant to the pharmaceutical industry. He is considered a subject matter expert in several areas including biosimilars, digital health and ESG and speaks at numerous conferences worldwide, presents at board-level meetings and engages in consulting projects.

Tomaž Bratkovič

Elektronska pošta/e-mail: tomaz.bratkovic@ffa.uni-lj.si

Ustanova / Institution: Univerza v Ljubljani, Fakulteta za farmacijo, Katedra za farmacevtsko biologijo

Kratka predstavitev / Short introduction:

Tomaž Bratkovič je izredni profesor na Fakulteti za farmacijo Univerze v Ljubljani ter predstojnik Katedre za farmacevtsko biologijo. Kot predavatelj sodeluje pri več učnih enotah s področij celične in molekularne biologije ter farmacevtske biotehnologije na študijskih programih, ki jih organizirata UL FFA in UL BF. Med letoma 2011 in 2016 je bil član Ekspertne skupine 6 (biološke snovi) pri Evropski farmakopeji (Evropski direktorat za kakovost zdravil, Strasbourg, Francija)

Tomaž Bratkovič is an associate professor at the Faculty of Pharmacy, University of Ljubljana, and head of the Department of Pharmaceutical Biology. As a lecturer, he contributes to several courses in the fields of cellular and molecular biology and pharmaceutical biotechnology in study programs organized by the University of Ljubljana, Faculty of Pharmacy, and the University of Ljubljana, Faculty of Biology. Between 2011 and 2016, he was a member of Expert Group 6 (biological substances) at the European Pharmacopoeia (European Directorate for the Quality of Medicines, Strasbourg, France).

Simona Borštnar

Elektronska pošta/e-mail: sborstnar@onko-i.si

Ustanova / Institution: Onkološki inštitut Ljubljana

Kratka predstavitev / Short introduction:

Doc. dr. Simona Borštnar je specialistka internistične onkologije in interne medicine na Onkološkem inštitutu v Ljubljani. Leta 2003 je doktorirala iz klinične onkologije. V letu 2006 se je izobraževala na onkološkem centru MD Anderson Houston. Že več kot 10 let je vodja multidisciplinarnega tima za rak dojke in predsednica Združenja za senologijo pri SZD. Je tudi predsednica komisije za oceno protokolov raziskav na Onkološkem inštitutu.

Je glavna raziskovalka v številnih kliničnih študijah raka dojke in govornica na več onkoloških konferencah doma in v tujini. Njeno bibliografijo sestavlja 500 enot: od tega več kot 40 raziskovalnih člankov.

Assoc. Prof. Dr. Simona Borštnar is a specialist in medical oncology and internal medicine at the Institute of Oncology in Ljubljana. She received her PhD in clinical oncology in 2003. In 2006, she underwent training at the MD Anderson Cancer Center in Houston. For over a decade, she has been the head of the multidisciplinary breast cancer team and the president of the Senology Association of the Slovenian Medical Association. She is also the chair of the protocol review committee at the Institute of Oncology.

She is the principal investigator in numerous clinical breast cancer studies and a speaker at various oncology conferences both domestically and internationally. Her bibliography comprises 500 units, including over 40 research articles.

David Drobne

Elektronska pošta/*e-mail*:

Ustanova / *Institution*: UKC Ljubljana, KO za gastroenterologijo

Kratka predstavitev / *Short introduction*:

Zaposlen je kot gastroenterolog na Kliničnem oddelku za gastroenterologijo UKC Ljubljana in kot docent na Katedri za Interno medicino Medicinske fakultete v Ljubljani. Njegovo ožje subspecialno področje delovanja je kronična vnetna črevesna bolezen. Poleg kliničnega dela z bolniki s kronično vnetno črevesno boleznijo sodeluje tudi v različnih raziskovalnih projektih s tega področja. Njegove raziskave so usmerjene v farmakokinetiko bioloških zdravil. Na njegovem oddelku vodijo eno večjih evropskih kohort s kronično vnetno črevesno boleznijo, zato se tudi uspešno vključujejo v mednarodne projekte.

He is employed as a gastroenterologist at the Clinical Department of Gastroenterology, University Medical Centre Ljubljana, and as an assistant professor at the Department of Internal Medicine, Faculty of Medicine, University of Ljubljana. His subspecialty is chronic inflammatory bowel disease. In addition to clinical work with patients with chronic inflammatory bowel disease, he is also involved in various research projects in this field. His research focuses on the pharmacokinetics of biological drugs. His department leads one of the largest European cohorts with chronic inflammatory bowel disease, which allows for successful participation in international projects.

Jurij Fürst

Elektronska pošta/e-mail: jurij.furst@zzzs.si

Ustanova / Institution: ZZZS, Oddelek za zdravila

Kratka predstavitev / Short introduction:

Po končani Medicinski fakulteti v Ljubljani 1981 je sprva delal v Psihiatrični bolnišnici Ormož in nato v Zdravilišču Rogaška. Leta 1991 je končal specializacijo iz interne medicine in delal v kardiološki ambulanti. Podiplomski študij iz klinične farmakologije na Medicinski fakulteti v Zagrebu je zaključil z magisterijem l. 2001. Od leta 1999 je zaposlen na Zavodu za zdravstveno zavarovanje Slovenije kot vodja oddelka za zdravila. Sočasno je v obdobju od 2001 – 2022 delal enkrat tedensko v diabetološki ambulanti Splošne bolnišnice Celje.

Najpomembnejša naloge oddelka za zdravila ZZZS so zagotavljanje financiranja primerne nabora zdravil in živil za posebne zdravstvene namene z razumnimi cenami in zagotavljanje drugih pravic zavarovanih oseb.

After graduating at the Faculty of Medicine in Ljubljana in 1981, he worked first at the Ormož Psychiatric Hospital and then at Zdravilišče Rogaška. In 1991 he completed his specialization in internal medicine and worked in a cardiology outpatient clinic. He completed his postgraduate studies in Clinical Pharmacology at the Faculty of Medicine in Zagreb with a Master's degree in 2001. Since 1999 he has been employed at the Health Insurance Institute of Slovenia (ZZZS) as Head of the Medicines Department. Additionally, he worked once a week in the Diabetology Outpatient Clinic of Celje General Hospital from 2001 - 2022.

The most important tasks of the Medicines Department of the Health Insurance Fund (ZZZS) are to ensure the financing of medicines and foods for special medical purposes at reasonable prices and to ensure other rights of insured persons.

Iztok Holc

Elektronska pošta / e-mail: iztok.holc@ukc-mb.si

Ustanova / Institution: Oddelek za revmatologijo, Klinika za interno medicino, UKC Maribor

Kratka predstavitev / Short introduction:

Prim. doc. dr. Iztok Holc, dr. med. specialist interne medicine in revmatologije, je predstojnik Oddelka za revmatologijo Klinike za interno medicino UKC v Mariboru. Kot docent za področje interne medicine je vključen v pedagoški proces na Medicinski fakulteti in Fakulteti za zdravstvene vede Univerze v Mariboru. Ob rednem kliničnem delu se ukvarja tudi z znanstveno raziskovalnim delom. Posebno veselje mu predstavlja ultrazvok v revmatologiji.

Assoc. Prof. Dr. Iztok Holc, MD, a specialist in internal medicine and rheumatology, is the head of the Department of Rheumatology at the Clinic of Internal Medicine, University Clinical Centre Maribor. As an associate professor in the field of internal medicine, he is involved in the teaching process at the Faculty of Medicine and the Faculty of Health Sciences, University of Maribor. In addition to his regular clinical work, he is also engaged in scientific research. He is particularly interested in the use of ultrasound in rheumatology.

Boštjan Jovan

Elektronska pošta / e-mail: bostjan.jovan@kclj.si

Ustanova / Institution: Univerzitetni klinični center Ljubljana

Kratka predstavitev / Short introduction:

Njegova poklicna kariera se je začela leta 2003 na Onkološkem inštitutu v enoti za intenzivno terapijo, kjer je sodeloval pri posodobitvi strokovnih standardov v zdravstveni negi in napisal standard za zdravstveno nego bolnikov s torakalno drenažo. Udeležil se je tudi "fast track" obravnave bolnikov po operacijah, o čemer je leta 2007 napisal strokovni prispevek.

Leta 2008 se je pridružil Kliničnemu oddelku za hematologijo, kjer je po dveh letih prevzel vlogo pedagoške medicinske sestre. Skrbi za strokovno izobraževanje zaposlenih, mentorira novo zaposlene diplomirane medicinske sestre in nadzoruje študente ter dijake. Od leta 2013 je habilitiran strokovni sodelavec Zdravstvene fakultete v Ljubljani in somentor diplomskih nalog s področja hematologije.

V sodelovanju z Zavodom za transfuzijsko medicino je opravil tečaj preskrbe in zdravljenja s krvjo ter se udeležuje strokovnih izobraževanj v Sloveniji. Od leta 2019 je predsednik Sekcije medicinskih sester in zdravstvenih tehnikov v hematologiji, kjer organizira izobraževanja in predava. Redno se udeležuje mednarodnih izobraževanj, s čimer prenaša znanje v prakso in širi znanja po Sloveniji.

His professional career began in 2003 at the Oncology Institute in the intensive care unit, where he contributed to the updating of nursing standards and authored guidelines for nursing care of patients with thoracic drains. He also participated in the "fast track" care of post-operative patients, on which he published a professional article in 2007.

In 2008, he joined the Clinical Department of Hematology, where he took on the role of pedagogical nurse after two years. He is responsible for the professional education of staff, mentoring newly hired registered nurses, and supervising students. Since 2013, he has been an academic associate at the Faculty of Health Sciences in Ljubljana and co-supervises theses in the field of hematology.

In collaboration with the Blood Transfusion Institute, he completed a course on blood supply and treatment and participates in professional training in Slovenia. Since 2019, he has been the chair of the Nursing and Health Technicians Section in Hematology, where he organizes education and lectures. He regularly attends international training, applying knowledge in practice and expanding it throughout Slovenia.

Tomislav Laptoš

Elektronska pošta / e-mail: tomi.laptos@kclj.si

Ustanova / Institution: Univerzitetni klinični center Ljubljana, Lekarna

Kratka predstavitev / Short introduction:

Tomislav Laptoš, magister farmacije, specialist klinične farmacije, je zaposlen v Lekarni UKC Ljubljana od leta 2006, kjer sodeluje pri pripravi zdravil iz nevarnih učinkovin. Razvija optimalne poti za zdravljenje posebnih bolnikov, zlasti pri tekočih peroralnih oblikah. V multidisciplinarnem timu obravnava predvsem transplantirane nefrološke pediatrične bolnike. Od leta 2014 razvija informacijske rešitve za elektronsko predpisovanje zdravil ter je aktiven predavatelj in mentor v lekarniški dejavnosti.

Tomislav Laptoš, Master of Pharmacy and specialist in clinical pharmacy, has been employed at the UKC Ljubljana Pharmacy since 2006, where he participates in the preparation of medications from hazardous substances. He develops optimal treatment pathways for specific patients, particularly concerning liquid oral forms. In a multidisciplinary team, he primarily addresses the needs of pediatric nephrology transplant patients. Since 2014, he has been involved in the development of an information solution for electronic prescribing of medications and is an active lecturer and mentor in pharmacy practice.

Matjaž Sever

Elektronska pošta / e-mail: matjaz.sever@kclj.si

Ustanova / Institution: Univerzitetni klinični center Ljubljana

Kratka predstavitev / Short introduction:

Prof. dr. Matjaž Sever je uveljavljen slovenski hematolog in raziskovalec s področja hematoloških malignomov in celičnih terapij. Po diplomu iz medicine na Medicinski fakulteti v Ljubljani leta 2002 se je specializiral iz interne medicine in hematologije. Svoje znanje je nadgradil z enoletnim postdoktorskim izobraževanjem na Oddelku za levkemije, MD Anderson Cancer Center, University of Texas, Houston, ZDA pod mentorstvom dr. Srdjana Verstovška, kjer se je posvetil mieloproliferativnim novotvorbam.

V letih 2014/15 se je izobraževal in delal v transplantacijski enoti Hammersmith Hospital, Imperial College London, kjer se je usposobil za transplantacijsko delo v skladu z mednarodno akreditacijo JACIE. Po vrnitvi v Slovenijo je prevzel vodenje transplantacij in naprednih celičnih terapij na Kliničnem oddelku za hematologijo UKC Ljubljana.

Njegovo raziskovalno delo obsega širok spekter področij, od simulacij kardiovaskularnega sistema do razvoja novih celičnih terapij, kot so CAR-T celične terapije in genska terapija. Je vodja in sodelavec številnih raziskovalnih projektov ter avtor številnih znanstvenih publikacij. Celotna bibliografija je dostopna na

<https://bib.cobiss.net/biblioweb/biblio/si/slv/conor/38069859>.

Prof. Dr. Matjaž Sever is an established Slovenian hematologist and researcher in the field of hematological malignancies and cellular therapies. After graduating in medicine from the Faculty of Medicine in Ljubljana in 2002, he specialized in internal medicine and hematology. He furthered his knowledge with a one-year postdoctoral fellowship at the Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, USA, under the mentorship of Dr. Srdjan Verstovšek, where he focused on myeloproliferative neoplasms.

In 2014/15, he trained and worked in the transplantation unit at Hammersmith Hospital, Imperial College London, where he acquired expertise in transplantation work in accordance with the international JACIE accreditation. Upon his return to Slovenia, he took over the leadership of transplantation and advanced cellular therapies at the Department of Hematology, University Clinical Centre Ljubljana.

His research covers a wide range of areas, from cardiovascular system simulations to the development of new cellular therapies such as CAR-T cell therapies and gene therapy. He is the leader and collaborator on numerous research projects and the author of numerous scientific publications. His complete bibliography is available at
<https://bib.cobiss.net/biblioweb/biblio/si/slv/conor/38069859>.

Povzetki in izročki predavanj

Lecture Abstracts and Handouts

Podobna biološka zdravila: kaj so in kako jih razvijajo?

Biosimilars: what are they, how are they developed?

Tomaž Bratkovič

Fakulteta za farmacijo, Univerza v Ljubljani

Povzetek

Podobna biološka zdravila (PBZ) so biološka zdravila, ki so zelo podobna drugim biološkim zdravilom, že odobrenim v EU (t. i. referenčnim zdravilom ali RZ). Manjše razlike med PBZ in RZ so neizogibne, kar je posledica kompleksnosti bioloških učinkovin in proizvodnih procesov. Vendar pa je z obsežnim primerjalnim vrednotenjem kakovosti (tj. fizikalno-kemijskih, strukturnih in bioloških lastnosti), dopolnjenim z manjšimi kliničnimi raziskavami, mogoče potrditi, da te razlike niso klinično pomembne, kar pomeni, da ni pričakovati razlik v učinkovitosti in varnosti med PBZ in RZ.

Če dokažemo visoko stopnjo podobnosti med PBZ in RZ ter primerljiv varnostni profil in učinkovitost, lahko te podatke ekstrapoliramo na vse terapevtske indikacije, za katere je že odobreno RZ. S tem se izognemo nepotrebnemu ponavljanju obsežnih kliničnih raziskav, kar občutno zniža stroške razvoja PBZ in omogoči širšemu krogu bolnikov dostop do enako kakovostnih, učinkovitih in varnih bioloških zdravil.


V EU imamo skoraj dvajsetletne izkušnje s PBZ. Opazovalne raziskave potrjujejo, da preklap z RZ na PBZ ali med različnimi PBZ ni povezan z varnostnimi tveganji.

Abstract


Biosimilars (BS) are biological medicines that are highly similar to other biological medicines already approved in the EU (the so-called reference medicines or RM). Minor differences between BS and RM are unavoidable due to the complexity of biological substances and manufacturing processes. However, extensive comparative assessments of quality (i.e., physicochemical, structural, and biological properties), supplemented by smaller clinical studies, can confirm that these differences are not clinically significant, meaning that no differences in efficacy and safety between BS and RM are expected.

If a high degree of similarity between BS and RM is demonstrated, along with a comparable safety profile and efficacy, this data can be extrapolated to all therapeutic indications for which the RM has already been approved. This avoids unnecessary repetition of extensive clinical studies, significantly reducing the costs of developing BS and providing broader access for patients to equally high-quality, effective, and safe biological medicines.


In the EU, we have nearly twenty years of experience with BS. Observational studies confirm that switching from RM to BS or between different BS is not associated with safety risks.



1



2



3

Proizvodnja bioloških zdravil

- proizvodni proces določa kakovost biološke učinkovine/zdravila ('The process IS the product!')
- zahtevana robustnost proizvodnega procesa

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

Al-Sabbagh et al., Sem Arthritis Rheum 2016

4

Zapletenost bio(tehno)loških učinkovin

- **strukturna zapletenost** (velikost, zvitje, disulfidne vezi, več domen/podenot, raznolikost PTM (npr. profil glikozilacije)...)
 - težka veriga
 - lahka veriga
 - glikan
- **funkcijska zapletenost** (več mehanizmov delovanj)
- primer monoklonskih protiteles:

Vsi deli mAb določajo učinkovitost in varnostni profil.

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

5

Zapletenost bio(tehno)loških učinkovin

- **variabilnost bioloških učinkovin/zdravil:**
 - izbor ekspresijskega sistema (celične linije)
 - bioprocesni pogoji (UPS)
 - izolacija in čiščenje (DSP)
 - formulacija
 - stabilnost
- vselej **mikroheterogenost**
- **variabilnost med serijami**
- obsežna sofisticirana analitika (komplementarne tehnike)

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

6

Podobno biološko zdravilo (PBZ)



- biološko zdravilo, ki je zelo **podobno drugemu**, v EU že **odobrenemu biološkemu zdravilu** (tako imenovanemu **referenčnemu zdravilu** (RZ))
- manjše **razlike** med PBZ in RZ vselej prisotne, a **niso klinično pomembne** (ni pričakovati razlik v učinkovitosti in varnosti!)
- potrebno dokazati visoko stopnjo podobnosti **strukture**, **biološke aktivnosti** in **učinkovitosti**, **varnosti** ter **profila imunogenosti**
- naslanjanje na izkušnje o učinkovitosti in varnosti, pridobljene pri referenčnem zdravilu → ponavljanje kliničnih vrednotenj nepotrebno
- obsežno **primerjalno vrednotenje** PBZ in RZ

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

7

PBZ niso "biogeneriki"!

LASTNOST	GENERIK	PODOBNO BIOLOŠKO ZDRAVILLO
Molekulska masa učinkovine	>500-900 Da	4-150 kDa (in več)
Struktura	enostavna	zapletena, variabilnost
Način pridobivanja	sinetno – identična kopija	posebej prirejen bioproces - podobna (a nikoli identična) kopija
Zapletenost	razmeroma nizka – možno popolno ovrednotenje	prisotna heterogenost – težavno vrednotenje razlik
Zahteve	podatki o kakovosti, bioekivalentnost	popoln dosje kakovosti, dokaz podobnosti (comparability exercise) : kakovost, varnost, učinkovitost

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

8

PBZ v EU: trenutno cca. 89 različnih

- odobritev sledi **centraliziranemu postopku** (EMA)
- EU na tem področju orala ledino (koncept PBZ uveden v legislativo že l. 2004, prvo PBZ odobreno l. 2006 (v ZDA šele l. 2015))
- splošne (kakovostne, neklinične, klinične) in produktno specifične smernice EMA (inzulini, somatropin, G-CSF, epoetini, IFN β , FSH, mAb, nizkomolekularni heparini)
- EMA priporočila odobritev že 106 PBZ; nekatere proizvajalci umaknili iz ekonomskih razlogov

<https://www.gabionline.net/biosimilars/general/biosimilars-approved-in-europe>

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

9



Primer - infliksimab

A Review of the Totality of Evidence for the Development and Approval of ABP710 (AVSOLA), an Infliximab Biosimilar

Walter Ritschard - Stanley Cohen - Monica Ranzanbach -
Miguel Khushf - Jennifer Liu - Vincent Chow - Janet Fardila -
Juan-Pablo Colaneri

- neklinična podobnost: mehanizmi delovanja ("PD in vitro")
 - afiniteta in kinetika vezave $\text{TNF-}\alpha$ in FcR1IIa ter FcRn
 - celični testi (nevtralizacija $\text{TNF-}\alpha$, ADCC, CDC, ADCP, neposredno proženje apoptoze...)

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

13

Primer - infliksimab

A Review of the Totality of Evidence for the Development and Approval of ABP710 (AVSOLA), an Infliximab Biosimilar

Walter Ritschard - Stanley Cohen - Monica Ranzanbach -
Miguel Khushf - Jennifer Liu - Vincent Chow - Janet Fardila -
Juan-Pablo Colaneri

- klinična podobnost: PK (zdravi prostovoljci) & primerjalna klinična raziskava (bolniki z RA)
 - bioekvivalenčna raziskava (enkratni odmerek), varnostni profil, imunogenost
 - klinična raziskava – občutljivi in objektivni izidi

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

14

Primer - infliksimab

A Review of the Totality of Evidence for the Development and Approval of ABP710 (AVSOLA), an Infliximab Biosimilar

Walter Ritschard - Stanley Cohen - Monica Ranzanbach -
Miguel Khushf - Jennifer Liu - Vincent Chow - Janet Fardila -
Juan-Pablo Colaneri

- klinična podobnost: primerjalna klinična raziskava (bolniki z RA)
 - klinična raziskava – varnostni profil, imunogenost

Table 1. Safety and immunogenicity of ABP710 and infliximab reference product (RP) in patients with rheumatoid arthritis (RA).

Safety	Through week 52		Post-week 52 (after single intravenous infusion)	
	ABP710	RP	ABP710	RP
Any AE, n (%)	144 (100)	136 (100)	69 (100)	69 (100)
Any AE with onset of death, n (%)	1 (0.6)	1 (0.6)	0 (0)	0 (0)
Any AE leading to infusion discontinuation, n (%)	30 (20.8)	30 (20.8)	11 (15.9)	11 (15.9)
Before infusion, n (%)	17 (11.8)	17 (11.8)	9 (13.0)	9 (13.0)
Upper respiratory tract infection, n (%)	17 (11.8)	17 (11.8)	9 (13.0)	9 (13.0)
Pharyngitis, n (%)	11 (7.6)	11 (7.6)	4 (5.8)	4 (5.8)
Hypertension, n (%)	9 (6.2)	9 (6.2)	4 (5.8)	4 (5.8)
Serious infection, n (%)	2 (1.4)	2 (1.4)	1 (1.4)	1 (1.4)
Malignancy, n (%)	2 (1.4)	2 (1.4)	0 (0)	0 (0)

Immunogenicity

Antibody positive by week 52: 144 (100) for ABP710, 136 (100) for RP. Antibody positive with a negative or no result at baseline: 144 (100) for ABP710, 136 (100) for RP. Antibody positive post-week 52 with a negative or no result at week 52 (after single intravenous infusion): 17 (11.8) for ABP710, 17 (11.8) for RP.

Strand et al., Nat Rev Rheumatol 2020

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

15

16

17

18



19

Podobna biološka zdravila: Zakaj so dobra za nas?

Biosimilars: why are they good for us?

Arnold G. Vulto

Erasmus University Medical Center, Dept. Of Hospital Pharmacy, Rotterdam, The Netherlands

Povzetek

Podobna biološka zdravila se na trg skoraj vedno uvedejo po nižji ceni kot referenčna zdravila. S tem se na trgu ustvari konkurenca, ki vodi k nižjim cenam – ne le za podobna biološka zdravila, temveč tudi za referenčna in običajno tudi za celotno terapevtsko kategorijo zdravil. Če se to zgodi, se stroškovna učinkovitost bioloških zdravljenj izboljša. Posledično lahko pride do povečanega in zgodnejšega dostopa bolnikov do zdravljenja, odvisno od tega, kako je organiziran zdravstveni sistem. Na koncu to izboljša kakovost oskrbe in zdravje bolnikov.

V nekaterih zdravstvenih sistemih prihranki, ki jih ustvarijo podobna biološka zdravila, omogočajo prostor v proračunu za zdravila za draga nova zdravljenja. V Evropi so podobna biološka zdravila ustvarila prihranke v višini približno 10 % celotnega proračuna za zdravila, in to ob hkratnem ohranjanju enakih standardov učinkovitosti in varnosti. Za izboljšanje trajnosti zdravstvenega sistema ni boljšega načina, kot je uvajanje podobnih bioloških zdravil. V predstavitvi bo prikazanih več primerov.

Literatura:

Dutta et al. BioDrugs (2020) 34:159–170: Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!

<https://gbiomed.kuleuven.be/english/research/50000715/52577001/mabel/Keyinsights>

Abstract

Biosimilars are almost always introduced at a lower cost than the reference product. The resulting competition in the market leads to lower prices, not only from the biosimilar, but also for the reference product and usually also for a whole therapeutic category. If this happens, the cost-effectiveness of biological treatments is getting better. This may result in increased and earlier access of patients to treatment, depending on how the health system is organised. In the end, it will improve the quality of care and the health of patients.

In some health systems the savings induced by biosimilars gives headroom in the drug budget for expensive new treatments. Europe wide biosimilars have generated around 10% savings on the total drug budget. And this while maintaining the same standards for efficacy and safety. There is no better way of improving the sustainability of health care system. In the presentation several examples will be shown.

Reference: Dutta et al. BioDrugs (2020) 34:159–170: Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!

<https://gbiomed.kuleuven.be/english/research/50000715/52577001/mabel/Keyinsights>

Biosimilar Symposium Slovenian Pharmaceutical Society, Hospital Pharmacy Section
Ljubljana, November 5, 2024

Biosimilars: Why are they good for us

Prof. Dr. Arnold G. Vulto F.C.P.
Hospital Pharmacist n.p. / Pharmacologist
ErasmusMC Rotterdam / KU Leuven Belgium
a.vulto@gmail.com

© VuPEC ErasmusMC KU LEUVEN
Handout 24k01

Who is Arnold Vulto?

- I was until May 1, 2018 a practising hospital pharmacist. I am not a lawyer nor regulator
- Member of ErasmusMC Medical Ethical Review Board (2006 – 2018)
 - In the pharmacy we see and run all drug trials
- Qualified Person (QP) for biotechnology medicines
- Got involved in biosimilars as early as 2004 via European Journal of Hospital Pharmacy
 - How to guide hospital pharmacists in this difficult area
- 2008 Founder of GaBI, together with Huub Schellekens and Lasia Tang
 - To provide transparency to cost-effective medicines
- 2013 Co-founder of the Dutch Biosimilar Initiative
- 2015: Co-founder of the MABEL-research fund (KU Leuven / ErasmusMC)

My motto: For each patient the best medicine at the best price

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

Biosimilars are essential for the sustainability of every healthcare system

- Innovative medicines are key to the advancement of medical science
 - Are in general very expensive, unaffordable, limited access
 - Almost 50% of the current EU-market (by value) are biological medicines
- Biosimilars are high quality biologics usually (much) lower priced:
 - More affordable
 - More accessible
 - Proven efficacy and safety, > 10 years of real world evidence (RWE)
- From a public health perspective they can play an essential role in the advancement of health of a population as a whole.
- Therefore it is deplorable that there is such variable access / uptake in Europe, while EMA has done a tremendous good job.

What are the gains for Europe?

- Cumulative savings (2012-2023): > 50 billion euros
- Annual savings around 10% of the TOTAL drug budget
- This is unprecedented in the history of health economics
 - No other measure ever achieved this
 - Biosimilars are the single most effective means to save money in the drug budget

11

BioDrugs
<https://doi.org/10.1007/s40259-019-00395-w>

REVIEW ARTICLE

Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!

Binita Dutta¹ · Isabelle Huys¹ · Arnold G. Vulto^{1,2} · Steven Simoons¹


Competition in European off-patent biologics and biosimilar markets may expand access to the treatment, improve cost effectiveness of the treatment, increase the number of healthcare professionals, and stimulate an incremental therapeutic innovation.



1. Biosimilars induce price competition

- Due to the availability of lower cost alternatives, competition in the market is driving prices down
 - Also the cost of the innovator usually goes down (initially with a larger overall impact than just biosimilar sales)
 - We also see that the drug cost in a total therapeutic group goes down

15



2. Improved cost-effectiveness

- New indications are opening up for patients, for which treatments with the innovator product was not cost-effective (and therefore not reimbursed in many countries)

16



3. Expanded patient access

- As the annual treatment cost per patient decreases, more patients can be treated with biologics for the same (or sometimes: less) budget

17



4. Earlier patient access

- Have you wondered why many patients got access to effective treatments in a late stage disease, missing the opportunity for cure?
- Due to lower cost of biologics, patients can be treated in an earlier stage of their disease (from 3rd line → 2nd line → 1st line)
 - This has a major positive effect on patient outcomes
- We see that treatment guidelines Europe wide are being adapted (ECCO, ESMO, EULAR etc.)

18

5. Headroom for innovation

- Biosimilar savings can be re-invested in healthcare for e.g.
 - New services / additional staff
 - Improving patient care
 - Budget room for innovative new medicines

19

Example: Biosimilar savings in The Netherlands (2015–2022), five molecules

Number of patients treated increased by +30%, while costs per patient decreased by an average of 70%

Molecule	Spending 2015 (M€)	Spending 2022 (M€)	Savings per molecule	Growth in no. of patients	Reduction in treatment costs per patient
Adalimumab	220.0	55.3	-75%	+86%	-87%
Etanercept	148.4	23.1	-84%	+2%	-85%
Infliximab	154.6	52.3	-66%	+50%	-77%
Rituximab	61.7	18.0	-71%	+49%	-80%
Trastuzumab	77.7	20.8	-66%	+12%	-70%
Total	662.4	169.5			

Numbers calculated from data in Dutch GDP Database. Available at: <https://www.gdpdatabase.nl/>

Take home message

- The biosimilar-story is much more than just about money
 - It's about wellbeing of patients and improving treatment outcomes
- Therefore: no healthcare system can afford NOT to have biosimilars
- As hospital pharmacists we have to behave responsibly to secure the future of a healthy biosimilar market.
- I will come back to that in my later presentations today.

23

Podobna biološka zdravila: Kateri so ključni dejavniki za uspeh?

Biosimilars: What are the key factors for success? The European Landscape

Aurelio Arias

IQVIA

Povzetek

V tem predavanju bomo preučili konkurenčno dinamiko na evropskem trgu z vpogledom v najnovejše trende sprejemanja pomembnih novih podobnih bioloških zdravil. Ocenjena bo konkurenca ne samo med primerljivimi podjetji, temveč tudi s strani originatorjev, kar bo zagotovilo celovit pregled konkurenčnega okolja.

Poleg tega bomo prikazali, kako se zdravniške preference glede komunikacijskih kanalov premikajo proti informacijam na zahtevo in kako se razlikujejo odnosi do preferenc bolnikov med različnimi terapevtskimi področji. Nazadnje bomo preiskali različne strategije, ki jih lahko podjetje uporabi za zagotovitev komercialnega uspeha v vse bolj prenatrpanem poslovnem okolju.

Abstract

This session will examine the competitive dynamics in the European market by taking a view at the latest uptake trends of important new biosimilar launches. Competition, not only from peer companies, will be assessed, but also from originators, providing a holistic competitive overview.

Moreover, we will show how physician preference of communication channels is shifting towards on-demand information and the differences in attitudes towards patient preference between therapy areas. Lastly, we will investigate the various strategies a company can employ to ensure commercial success in an increasingly crowded environment.




What are the key factors for success? The European Landscape

16th International Symposium; Section of Hospital Pharmacists of the Slovenian Pharmaceutical Society


Aurelio Arias
Director, EMEA Thought Leadership

© 2024. All rights reserved. IQVIA is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.

0




1




2






6



7



8

Podobna biološka zdravila: ekstrapolacija indikacij namesto kliničnih raziskav

Biosimilars: extrapolation of indications instead of clinical trial

Arnold G. Vulto

Erasmus University Medical Center, Dept. Of Hospital Pharmacy, Rotterdam, The Netherlands

Povzetek

Razvoj podobnih bioloških zdravil temelji na dokazovanju, da se kandidat za podobno biološko zdravilo obnaša kot izdelek, ki posnema izvirnik (referenčni) izdelek. To se izvaja s kemičnimi, fizikalnimi in (kliničnimi) farmakološkimi tehnikami. Ta »postopek za podobno biološko zdravilo« se osredotoča na ključne lastnosti kakovosti (CQA), tiste lastnosti, ki so pomembne za učinkovitost in varnost (odsotnost neželenih učinkov) zdravila, vključno z imunogenostjo. Ko je podobnost dokazana, lahko pričakujemo, da se bo molekula obnašala enako pri vseh indikacijah, ki temeljijo na istem mehanizmu delovanja (kot je zaviranje TNF-alfa). Za regulatorje zadostuje klinična študija pri bolnikih z »najbolj občutljivo indikacijo« in z merili, ki lahko pokažejo morebitne razlike v aktivnosti, če te obstajajo. Naslednji korak je, da sponzor na podlagi literature ali z navajanjem referenčnega izdelka dokumentira ključne dejavnike za učinkovitost in varnost pri drugih indikacijah. Ti argumenti so pregledani s strani regulatornih agencij, in če so sprejeti kot znanstveno utemeljeni, se odobri ekstrapolacija na indikacije, ki niso bile testirane v formalni klinični študiji. Ko je izdelek registriran, je povsem običajno, da se podobno biološko zdravilo lahko predpisuje izmenično z izvirnim izdelkom in tudi z drugimi podobnimi biološkimi zdravili, ki se sklicujejo na isti referenčni izdelek.

Abstract

Developing biosimilars is all around proving that the candidate-biosimilar behaves as a look-alike of the innovator (reference) product. This is done with chemical, physical, and (clinical) pharmacological techniques. This »biosimilar exercise« is all about critical quality attributes (CQA), those attributes that matter for efficacy and safety (absence of side effects), of a medicine, including immunogenicity. Once the similarity has been proven, one might expect that the molecule will behave the same in all indications that are based on the same mechanism of action (like TNF-alfa inhibition). For regulators suffice a clinical test in patients with »the most sensitive indication« and with endpoints that are able to show any difference in activity, if this exists. The next step is that the sponsor documents – based on literature or referring to the reference product – the critical factors for efficacy and safety in the other indications. These arguments are examined by the regulatory agencies, and if accepted as being scientifically justified, the extrapolation to indications that have not been tested in a formal clinical trial will be granted. Likewise, when the product has been licensed, it is just natural that the biosimilar can be prescribed interchangeably with the originator product and also with other biosimilars referring to the same reference product.

Reference: Weise et al. Blood 124(2014)3191 Biosimilars: the science of extrapolation.



Biosimilar Symposium Slovenian Pharmaceutical Society, Hospital Pharmacy Section
Ljubljana, November 5, 2024

**When the molecule is the same, it will do the same:
indication extrapolation and interchangeability**

Prof. Dr. Arnold G. Vulto F.C.P.
Hospital Pharmacist n.p. / Pharmacologist
ErasmusMC Rotterdam / KU Leuven Belgium
a.vulto@gmail.com

©VuPEC Handout 24ik01

ErasmusMC KU LEUVEN



Agenda

- Introduction: the fundamentals of biosimilarity
- Extrapolation of indications
- Interchangeability
- Conclusion

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024



Introduction: the fundamentals of similarity

- Biosimilar company buys 10 – 20 batches of the innovator product
- Analyse these batches in great detail:
 - How does the molecule look like?
 - What are critical parts of the molecule for mode of action?
 - Determine the amino acid sequence + other critical aspects
 - This results in a "fingerprint" of the originator molecule + the inherent variation
- Then the DNA coding for the amino-acid sequence is cloned in a producer cell
- This results in hundreds of clones
 - These are analysed for resemblance to the originator molecule
 - And for sufficient yield to allow cost-effective production

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

In theory, a stepwise approach in the development of biosimilars (in practice much in parallel)

1. Technical qualifications of reference product (including variation).
This sets specifications for biosimilar candidate
2. Bioassays (for instance, on human cells)
3. Non-clinical tests in animals: by most agencies now seen as redundant
4. At least 1 clinical test in humans: one PK/PD, and if needed a patient trial in the most sensitive population with sensitive endpoints (i.e. *able to detect a difference* if there is one)
5. Specific post-marketing surveillance ("Risk Management Plan"), e.g. check for unexpected immunogenicity

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

The cornerstone of biosimilar development comparability studies

- Extensive comparison with the reference medicine
- Well-established scientific principle - evaluation of manufacturing changes during product life cycle
- Step-wise approach
- Assessment on the **totality of evidence** for similarity

Step 1

Comparative quality studies

- Analytical: physical + chemical properties
- Functional: biological/pharmacological activity

Step 2

Comparative non-clinical studies

- Pharmacodynamic
- Toxicology

Step 3

Comparative clinical studies

- Pharmacokinetic/pharmacodynamic
- Efficacy + safety + immunogenicity

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

Clinical development for biosimilars

Development of a new drug

Clinical trials

PK/PD

Development of a biosimilar

Clinical Trials

PK/PD

Goal clinical studies in the context of biosimilar development

- Not needed to demonstrate *de novo* efficacy and safety of the product - therapeutic benefit already established for RP; goal = **Confirm biosimilarity** to the RP
- Ensure **no clinically meaningful differences** in efficacy, safety, immunogenicity – tailored to **detect clinically meaningful differences** between products if these would be present
- Final step **totality of evidence**, stepwise reduction of **residual uncertainty**

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

10

- The idea is, that if biosimilars behave the same in the most sensitive indication (to detect a difference), that this absence of difference will be the same in other indications based on the same mechanism of action.
- This most sensitive indication may well be different from the trials performed with the reference product

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

12

Extrapolation of indications

= Approval for one or more indications for which the RP is approved, without being subjected to clinical testing in all these indications itself

- Well established regulatory principle → **avoid unnecessary clinical trials**
- Granted based on **totality of evidence** for similarity and **scientific justification** (mechanism of action is the same, testing in relevant study population)
- Can be perceived as challenging for prescribers (e.g., when extrapolating between different therapeutic areas) if they have no knowledge about the biosimilar paradigm, but it is an **essential component** of the biosimilarity pathway

Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. **Biosimilars: the science of extrapolation.** Blood. 2014;124:3191-6.

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

12

EMA principles for indication extrapolation

- Efficacy and safety in extrapolated indications has to be scientifically justified
 - (not a free ride; that's why we see differences in labels)
- Confidence in clinical experience with the reference product
- Mechanism of action in each indication should be the same
 - With similar patient factors (comorbidities, co-medication, immunogenicity)
- The degree to which functional moieties in the molecule can be characterised (e.g. with similar target receptors)
- Etc.

Selection of sensitive endpoints for biosimilar trastuzumab clinical trials

Primary endpoint may be different to those used for approval of the RP

Preferred endpoints for demonstrating efficacy (new product)	Recommended endpoints for demonstrating biosimilarity
- A clinical endpoint that measures survival - Overall survival (OS) - Disease-free survival (DFS) - Progression-free survival (PFS) May be not feasible/sensitive enough to demonstrate biosimilarity of a biosimilar mAb to the reference product	- A clinical endpoint that measures shorter-term activity Overall response rate (ORR) - Partial + complete response - In metastatic setting Pathologic complete response (pCR) - In neoadjuvant + adjuvant setting - Breast pCR or total pCR (breast + lymph nodes)

Barbier, L., et al. Br J Cancer 121, 199–210 (2019)

Example 2: infliximab

Active Substance	Brand Name	Approval Date
Infliximab (CT-P13)	Inflectra Remsima	September 2013 September 2013

Approved indications

Trial supported

- Ankylosing spondylitis
- Rheumatoid arthritis

Extrapolated

- Crohn's disease
- Psoriatic arthritis
- Psoriasis
- Ulcerative colitis

18

Clinical and epidemiological research

EXTENDED REPORT

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with **ankylosing spondylitis**: the PLANETAS study

2 x 125 patients
Result: biosimilar almost identical

Won Park,¹ Pavel Hrycaj,² Slavomir Jeka,³ V. Pedro Miranda,⁴ Helena Mikazane,⁵ Sergio Gi Yeon-Ah Lee,⁶ Sang Joon Lee,⁷ Ho-Jung Kim,⁸

Clinical and epidemiological research

EXTENDED REPORT

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with **active rheumatoid arthritis**: the PLANETRA study

2 x 300 patients
Result: biosimilar at least equal with reference product
Total: 54 weeks

Dae Hyun Yoo,¹ Pavel Hrycaj,² Pedro Miranda,³ Edgar Ramirrez,⁴ Mariusz Piotrowski,⁵ Sergii Shevchuk,⁶ Volodymyr Kovalenko,⁷ Nenad Prodanovic,⁸ Mauricio Abello-Barri,⁹ Sergio Gutierrez-Ureña,¹⁰ Luis Morales-Olazabal,¹¹ Michael Tee,¹² Renato Jimenez,¹³ Omid Zamani,¹⁴ Sang Joon Lee,¹⁵ Ho-Jung Kim,¹⁶ Won Park,¹⁷ Ulf Müller-Ladner¹⁸

19



Interchangeability

- EMA: on a population level the outcome of treatment with a biosimilar or reference product will be the same.
 - Has no legal meaning in memberstates
- FDA: a legal designation
 - Is not “a better” biosimilar: quality, efficacy and safety are te same
 - Is needed with respect to some state pharmacy ruling
- This difference between EU and US has caused a lot of confusion

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

21



The confusing terminology

- **Interchangeability:** EMA differs fundamentally from FDA
 - Very confusing: population versus individual level
- **Switching** is both:
 - Change from one treatment / molecule to another
 - Change from reference product to biosimilar (also confusingly coined *non-medical switching*).
 - Maybe better word **transitioning**: only for biosimilars (Dörner, 2016)
- **Substitution:**
 - Dispensing another drug as prescribed without consulting the prescriber
 - Why discuss? We generally don't do it (with few exceptions).

Weise et al. Nature Biotechnology 29, 690–693 (2011)

Dörner et al Ann Rheum Dis doi:10.1136/annrheumdis-2016-209166

Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective

Pekka Kurki¹ · Sean Barry² · Ingrid Bourges³ · Panagiota Tsantili⁴ · Elena Wolff-Holz⁵



Abstract

Background: Biosimilars have been used for 15 years in the European Union (EU), and have been shown to reduce costs and increase access to important biological medicines. In spite of their considerable exposure and excellent safety record, many prescribers still have doubts on the safety and interchangeability of biosimilars, especially monoclonal antibodies (mAbs) and fusion proteins.

Objective: The aim of this study was to analyse the short- and long-term safety and interchangeability data of bi mAbs and fusion proteins to provide unbiased information to prescribers and policy makers.

Methods: Data on the safety, immunogenicity and interchangeability of EU-licensed mAbs and fusion proteins were used using European Public Assessment Reports (EPARs) and postmarketing safety surveillance reports from the EU Medicines Agency (EMA). As recent biosimilar approvals allow self-administration by patients by the subcutaneous administration devices were also analysed.

Results: Postmarketing data of EPARs for different biosimilar adalimumabs, three infliximabs, three etanercepts, three mAbs, two bevacizumabs, and six trastuzumabs revealed that the frequency of fatal treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation of treatment, serious adverse events (SAEs), and main immune-mediated events (AEs) were comparable between the biosimilars and their reference products. The availability of new biosimilar emulations and administration devices may add to patient choice and be an emerging factor in the decision to switch.

Analysis of postmarketing surveillance data covering up to 7 years of follow-up did not reveal any biosimilar-specific effects. No product was withdrawn for safety reasons. This is in spite of considerable exposure to biosimilars in its naive patients and in patients switched from the reference medicinal product to the biosimilar. Analysis of data from studies provided in regulatory submissions showed that single or multiple switches between the originator and its bi versions had no negative impact on efficacy, safety or immunogenicity.

Conclusions: In line with previous reports of postmarketing studies of biosimilar mAbs and etanercept, this study demonstrates comparable efficacy, safety, and immunogenicity compared with the reference products. This is the first study to comparatively analyse postmarketing surveillance data of the biosimilar mAb and etanercept. An analysis of more than 10 patient treatment years of safety data raised no safety concerns. Based on these data, we argue that biosimilars approved in the EU are highly similar to and interchangeable with their reference products. Thus, additional systematic switch are not required to support the switching of patients.

- Study of short- and long-term safety and interchangeability data of biosimilar mAbs and fusion proteins
- Analysis of **more than 1 million patient-treatment years** of safety data raised no safety concerns.
- Based on these data, we argue that biosimilars approved in the EU are highly similar to and interchangeable with their reference products.
- Additional systematic switch studies are not required to support the switching of patients
- Drugs 81(2021)1881

Biosimilar interchangeability

Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU

Biosimilars approved in the EU are interchangeable (21 April 2023)

HMA and EMA consider that **once a biosimilar is approved in the EU it is interchangeable**, which means the biosimilar can be used instead of its reference product (or vice versa) or one biosimilar can be replaced with another biosimilar of the same reference product.

Decisions on how to implement interchangeability either through **switching** (under the control of the prescriber) **and/or substitution** (the practice of dispensing one medicine instead of another medicine without consulting the prescriber, such as automatic substitution at the pharmacy level), are not within the remit of EMA and are **managed by individual member states**.

https://www.ema.europa.eu/en/documents/public-statement/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines_en.pdf

Supported by a massive real-world-evidence (between 2006 – 2021)

5.8 billion patient treatment days
With EU approved biosimilar medicines since 2006



Conclusion

- Based on scientific pharmacological principles and extensive trial-experience + real world evidence we can:
 - Allow extrapolation of indications
 - (use a biosimilar in an indication not supported by a dedicated patient trial)
 - Use a reference product and its biosimilars interchangeably
 - Allowing the use of the most cost-effective product
- Hospital pharmacists have to include these principles in their education to raise trust in biosimilar prescribing

Podobna biološka zdravila: izkušnje s področja hematologije

Biosimilars: Experiences in Hematology

Matjaž Sever

Univerzitetni klinični center Ljubljana, Klinični oddelek za hematologijo

Povzetek


Biološka zdravila so ključna v hematologiji za zdravljenje različnih krvnih bolezni, kot so levkemije, limfomi in anemije. Podobna biološka zdravila (PBZ) so zelo podobna že odobrenim biološkim zdravilom in so klinično enakovredna originalnim zdravilom. Uporaba PBZ omogoča dostop do učinkovitih terapij po nižjih stroških, kar izboljša dostopnost zdravljenja za bolnike. PBZ so podvržena obsežnim primerjalnim študijam, da se zagotovi njihova varnost, učinkovitost in kakovost. V hematologiji se biološko podobna zdravila uporabljajo za zdravljenje različnih krvnih bolezni. Filgrastim je primer biološko podobnega zdravila, ki se uporablja za spodbujanje proizvodnje nevtrofilcev pri bolnikih z nevtropenijo. Rituksimab se uporablja za zdravljenje nekaterih vrst limfoma in kronične limfocitne levkemije. Epoetin alfa se uporablja za zdravljenje anemije pri bolnikih s kronično ledvično boleznijo, mielodisplastičnim sindromom ali pri tistih, ki prejemajo kemoterapijo.

Abstract

Biological drugs are essential in hematology for the treatment of various blood diseases, such as leukemias, lymphomas, and anemias. Biosimilar medicines (BSMs) are highly similar to already approved biological medicines and are clinically equivalent to the original drugs. The use of BSMs allows access to effective therapies at lower costs, improving treatment accessibility for patients. BSMs undergo extensive comparative studies to ensure their safety, efficacy, and quality. In hematology, biosimilar medicines are used to treat various blood diseases. Filgrastim is an example of a biosimilar medicine used to stimulate the production of neutrophils in patients with neutropenia. Rituximab is used to treat certain types of lymphoma and chronic lymphocytic leukemia. Epoetin alfa is used to treat anemia in patients with chronic kidney disease, myelodysplastic syndrome, or those receiving chemotherapy.



1



2

Odobreni epoetini in filgrastimi v EU

Molecule	INN	Brand name
HX575	Epoetin α	Binocrit® (Sandoz GmbH, Austria)
		Hexal® (Hexal Biotech, Germany)
		Abseamed® (Medice Arzneimittel Putter, Germany)
SB309	Epoetin ζ	Retracrit® (Hospira, USA)
		Silapro® (Stada, Germany)

INN: international nonproprietary name.

Trade name	INN	Biosimilar sponsor	Reference product
Binogristin®	Filgrastim	CT Arzneimittel GmbH	Neupogen®
Binogristin®	Filgrastim	Ratiopharm GmbH	Neupogen®
Binogristin®	Filgrastim	Ratiopharm GmbH	Neupogen®
Binogristin®	Filgrastim	Teva Generics GmbH	Neupogen®
Binogristin®	Filgrastim	Sandoz	Neupogen®
Binogristin®	Filgrastim	Hexal	Neupogen®
Binogristin®	Filgrastim	Hospira	Neupogen®

INN: international nonproprietary name.

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

Ther Adv Hematol 2015, Vol. 4(4) 267-281

3

- Biosimilar filgrastim (Sandoz) je bil odobren v Evropi leta 2009 in v ZDA leta 2015, ko je postal prvi biosimilar, ki ga je odobrila ameriška FDA.
- Klinične študije faze III so bile izvedene pri bolnikih z rakom dojke, ki so prejemali mielosupresivno kemoterapijo.
- Odobritev je bila nato podeljena za vse indikacije referenčnega biološkega zdravila na podlagi ekstrapolacije.
- Ekstrapolacija je dobro sprejeta v razvoju bioloških zdravil in regulativnih kontekstih.
- Več kot desetletje klinični izkušenj od odobritve podpira celovitost dokazov glede učinkovitosti in varnosti biosimilarnega filgrastima.

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2023

BioDrugs (2019) 33:635–645

Figure 1 consists of two line graphs. The left graph, titled 'Absolute Neutrophil Count', plots 'Mean ALC (x 10³)' on the y-axis (0 to 30) against 'Time (Days)' on the x-axis (1 to 21). It compares Nivolumab (squares) and Neupogen (circles). Nivolumab shows a sharp drop from ~25 to ~2 between days 4 and 6, then recovers to ~10 by day 11. Neupogen shows a similar but less severe drop, reaching ~4 at day 6 and recovering to ~10 by day 11. The right graph plots 'neutrophils (cells/mm³)' on the y-axis (0 to 40) against 'Time (Days)' on the x-axis (1 to 21). It compares Tevagrastim (circles) and Neupogen (squares). Tevagrastim shows a sharp drop from ~25 to ~10 between days 4 and 6, then recovers to ~20 by day 11. Neupogen shows a similar but less severe drop, reaching ~15 at day 6 and recovering to ~20 by day 11. Both graphs include error bars representing standard error.

- Nivestim vs Neupogen¹
- Tivagastim vs Neupogen²

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

1. Waller CF, et al. *Oncologie*. 2010;33(10):504-511.
2. *Compendium of Clinical Trials*. 2000;411:335-340.

- Pegfilgrastim se je izkazal za bolj učinkovitega od filgrastima pri zmanjševanju kemoterapije povezane nevtropenije in pri doseganju ciljne intenzivnosti odmerka, saj je slednji pogosto premalo odmerjen v klinični praksi.
- Uporaba biosimilarnega pegfilgrastima olajša dostop in, podprta s smernicami in kliničnimi rezultati, omogoča uresničitev celotnega potenciala pegfilgrastima po nižjih stroških.

Brand name	Manufacturer	Regenerative trial	EMA approval	FDA approval
<i>RegeneX</i> [®]	Accord Healthcare	Use of A-201 [26] Phase II randomized, assessor-blinded, multicenter study on 144 breast cancer patients with extensive arm of US-Northern and EU-Northern	September 2018	
<i>Urologix</i> [®]	Colson Medical	Dose-expansion trial Waller et al. [2017] [27] Phase II randomized, assessor-blinded study on 104 prostate cancer patients with extensive arm of EU-Northern	September 2018 November 2018	November 2018 June 2019
<i>PrimeX</i> [®]	Cialis Biotech/Mandipharma	Dose-expansion trial Harbeck et al. [2018] [28]	November 2018	
<i>Zenox</i> [®]	Sandoz	Phase II randomized, assessor-blinded, multicenter study on 141 breast cancer patients with extensive arm of EU-Northern and EU-Southern	November 2018	November 2018
<i>Genovex</i> [®]	Jans Pharma	Genovex (FAP-2) Phase II randomized, assessor-blinded, multicenter study on 254 breast cancer patients with extensive arm of EU-Northern	April 2019	
<i>Regeniviva</i> [®]	Mandipharma	Dose-expansion trial ^a	December 2019	

17. marcosrodol@simonoli.it / 12th International Symposium, Ljubljana, 5 november 2013

BioDrugs (2020) 34:255–262

Pegfilgrastim

Clinical benefits vs filgrastim (< 7 days)	Economic benefits vs reference pegfilgrastim
Reduced FN incidence	Cost savings > 30%
Reduced FN-related hospitalisations	Increased patient access
Reduced chemotherapy dose delays	Create additional budget for new medicines
Improved relative dose intensity	Financial sustainability
Improved adherence to G-CSF guidelines	Improved device/additional handling features
Reduced hospital visits and risk of nosocomial infections	
Improved patient acceptability and adherence	

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

BioDrugs (2020) 34:255–263

7

Pegfilgrastim

- Primarna profilaksa z G-CSF je ključna za bolnike na kemoterapijah z visokim tveganjem ($\geq 20\%$) ali srednjim tveganjem (10–20%) in dodatnimi dejavniki tveganja.
- Zagotavlja ohranjanje intenzivnosti odmerka terapije, kar izboljšuje preživetje bolnikov z rakom.
- Pegfilgrastim je boljši od filgrastima pri zmanjševanju nevtropenije in FN, izboljšanju skladnosti s smernicami G-CSF in doseganju ciljne RDI.
- Biosimilarni pegfilgrastim ponuja novo priložnost za ponoven razmislek o vodenju nevtropenije.
- Pomembne klinične in ekonomske koristi.
- Skupno, multidisciplinarno delovanje, ki vključuje predpisujoče zdravnike, onkološke medicinske sestre in farmacevte, podprto s smernicami in kliničnimi pravili, bo omogočilo uresničitev celotnega potenciala te pomembne terapije.

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

BioDrugs (2020) 34:255–263

8

Biosimilarji na področju presaditve

Original biologic	Biosimilar approved*	Year of approval (regulatory body)	Approved/possible uses in HCT
Filgrastim	Tecagrastim	2008 (EMA)	Mobilization of stem cells for auto-BCT
	Ratigrastim	2008 (EMA)	
	Filgrastim Hexal	2009 (EMA)	Mobilization of stem cells in allo-BCT
	Zarzio	2009 (EMA)	
	Accofil	2014 (EMA)	
	Zarzio	2015 (USFDA)	
Rituximab	Nivestim	2010 (EMA)	RCT donors
	Granoffi	2013 (EMA)	Cell recovery after transplant
	Nivestyn	2018 (USFDA)	
	Tecuma	2017 (EMA)	
Infliximab	Ricashen	2017 (EMA)	Chronic GVHD therapy
	Ricamvia	2017 (EMA)	Chronic GVHD prevention
	Ricimay	2017 (EMA)	
	Ricazima	2017 (EMA)	
	Ricazena	2017 (EMA)	
		2017 (EMA)	
Eltisimab	Inflectra	2013 (EMA)	Acute GVHD therapy
	Finabli	2016 (USFDA)	Acute GVHD prevention
	Reimima	2016 (EMA)	
	Reinflexis	2013 (EMA)	
	Leif	2017 (USFDA)	
	Zesoly	2017 (USFDA)	
Eltascept	Bencipali	2016 (EMA)	Acute GVHD therapy
	Eltis	2017 (EMA)	Therapy for BOS and IPS

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

Bone Marrow Transplantation (2020) 55:698–707

9

Biosimilarji na področju presaditve								
References	Type of Transplant	Biosimilar	Dose (µg/kg/day)	MM	NHL	HL	AML / ALL	GCT
Publicover A. et al. (2013)	Auto	Rituximab [®] / Ref. G-CSF + Chemo	NA	76	65	13	-	-
Kirschner H. (2011)	Auto	Rituximab [®] + Chemo	NA	7	11	1	-	1
Salmassidou S. et al. (2013)	Auto	Tecovastat [®] + Chemo	300µg/day	6	8	1	-	-
Sever M. et al. (2012)	Auto	Tecovastat [®]	30	-	-	-	-	-
Andriani G. et al. (2012)	Auto	Tecovastat [®] + Flt [®] + Chemo	30	8	4	2	-	-
Lenze F. et al. (2012)	Auto	Tecovastat [®] + Flt [®] + Chemo	NA	81	105	25	-	-
Ueda O. et al. (2012)	Auto	Ref. G-CSF / Tecovastat [®] + Flt [®] + Chemo	30	30	30	1	-	-
Morabito L. et al. (2012)	Auto	Ref. G-CSF / Tecovastat [®] + Flt [®]	30	3	1	-	-	-
Total				191	204	49	-	1

10

Rituximab	
- Uporablja se tudi pri revmatoidnem artritisu, kjer so B limfociti vključeni v vnetje sklepov, ter pri granulomatozi s poliangiitisom (GPA) in mikroskopski poliangiitis (MPA), kjer uničenje B limfocitov zmanjša proizvodnjo protiteles, ki napadajo krvne žile in povzročajo vnetje. - Obstajajo štiri možni mehanizmi delovanja anti-CD20 protiteles za uničenje B celic: (i) ADCC, (ii) CDC, (iii) apoptoza in (iv) fagocitoza malignih B celic. - V klinični praksi se mehanizmi delovanja lahko razlikujejo glede na indikacijo. - Do leta 2019 je bilo v EU licenciranih sedem biosimilarjev rituksimaba, ki vključujejo GP2013 (Sandoz) in CT-P10 (Celltrion). - Biosimilarji so bili testirani v različnih kliničnih indikacijah, EMA pa je odobrila vse indikacije referenčnega izdelka.	
HemaSphere (2019) 3:6(322)	

11

Rituximab	
- Licenciranje bioloških zdravil je v Evropi centralizirano, kar omogoča prosti pretok licenciranih zdravil med državami EU. - Sprejemanje biosimilarjev rituksimaba s strani predpisovalcev je bilo v Evropi relativno gladko po uvedbi TNF-alfa inhibitorjev infliksimaba in etanercepta. - V nekaterih državah, kot je Nizozemska, je bilo v treh mesecih po uvedbi 90% bolnikov prevedenih na biosimilarje. - Hematologi so že bili seznanjeni z biosimilarji - hematologija je bolj laboratorijsko usmerjena specialnost kot mnoge druge.	
HemaSphere (2019) 3:6(322)	

12



13

Podobna biološka zdravila: izkušnje s področja gastroenterologije in zdravljenja kronične vnetne črevesne bolezni

Biosimilars: Experiences in Gastroenterology and the Treatment of Chronic Inflammatory Bowel Disease

David Drobne


Univerzitetni klinični center Ljubljana, Klinika za gastroenterologijo

Povzetek


Podobna biološka zdravila smo privzeli za zdravljenje kronične vnetne črevesne bolezni v UKC Ljubljana med prvimi v Sloveniji in Evropi. Predstavil bom našo izkušnjo z infliximabom, ki je bilo prvo biološko zdravilo za področje kronične vnetne črevesne bolezni, kjer smo praktično čez noč napravili prehod iz originatorja na podobno biološko zdravilo. Predstavil bom bolnika z značilnim nocebo učinkom in zakaj je pomembno, da je t.i. »non-medical switch« vseeno vsaj malo tudi »medical«. Predstavil bom tudi aktualne podatke o rabi podobnih bioloških zdravil iz Registra kronične vnetne črevesne bolezni.

Abstract


At the University Medical Centre Ljubljana, we were among the first in Slovenia and Europe to introduce biosimilar drugs for the treatment of chronic inflammatory bowel disease. I will present our experience with infliximab, the first biosimilar drug for chronic inflammatory bowel disease, where we practically made an overnight switch from the originator to the biosimilar. I will present a case of a patient with a characteristic nocebo effect and explain why it is important that a so-called "non-medical switch" is at least somewhat "medical". I will also present current data on the use of biosimilar drugs from the Chronic Inflammatory Bowel Disease Registry.




1




2




3




4




5




6



7



8



9

Klinični oddelek za gastroenterologijo

2016: Med prvimi začnemo z uporabo podobnih bioloških zdravil

Obvestilo lekarne:
zdravilo Ramicade (originator infliximab) ne bo več na voljo, potrebno je
preklopiti vse bolnike na biosimilar (čez noč)

10

LETO 2016

- UKC LJ: odločitev o menjavi originatorja infliximab za biosimilar
- Nujna menjava
- Izjeme lahko bolniki, ki niso v remisiji

11

Zakaj je bilo to za nas presenečenje?




Figure 2: Forest plot of risk difference according to disease
Figure shows data for the per-protocol set. Risk difference is adjusted for treatment duration of infliximab originator at baseline.

Jorgensen Lancet 2017

12

Tranzicija skozi leta KVČB: 2016 do 2018

Datum	Vsi bolniki na biol. terapiji	Humira	Ramcade	Simponi	Remsima	Entyvio	Stelara
12/16	344	125	128	10	38	30	13
12/17	448	142	17	19	172	63	35
4/18	492	138	18	15	177	82	62

13

LETO 2018: infliximab biosimilar
177 bolnikov s KVČB

Novi bolniki (biosimilar kot prvo zdravilo): 94

Non-medical switch: 83

14

Outcome of non-medically switched patient with IBD (2018):

In total 115 pt:

- Still on biosimilar 83
- Discontinued: 32
 1. Back to reference IFX: 14 (disease flare, worsening skin lesions, arthralgia, open fistula, diarrhea, hair loss, etc)
 2. Vedolizumab: 5
 3. Ustekinumab: 4
 4. Discontinued: 4 (operation, remission, etc)
 5. Adalimumab: 2
 6. Other institution: 3

15

The nocebo phenomena: the negative equivalent of placebo

Placebo vs. nocebo

• **Nocebo effect:** the induction or the worsening of symptoms induced by sham or active therapies^{1,2}

• **Nocebo response:** new and worsening symptoms that are caused only by negative expectations on the part of the patient and/or negative verbal and non-verbal communications on the part of the treating person, without any (sham) treatment¹

1. Hróbjartsson A, et al. *Drugs* 2012;109:459-465.
2. Piana S, et al. *Pharmaceutical Risk* 2016;4:e00208.

16

Leto 2024

- UKC LJ KVČB:
 - Biosimilarji infliksimaba zdravilo izbora
 - Biosimilarji adalimumaba zdravilo izbora
 - Biosimilarji ustekinumaba: obdobje prehoda

17

Crohnova bolezen: razmerje originator/biosimilar Slovenija
- podatki iz registra za leto 2023

Utilisation of advanced treatments in inflammatory bowel disease in Slovenia - national report from URCARE Registry for the year 2023

Uporaba naprednih zdravil pri boleznih s krevratno vnetno črevesno boleznijo v Sloveniji - nacionalni podatki iz URCARE registra za leto 2023

Table 4. Number of patients, who remained on biologic in respective line of treatment for Crohn's disease (from inception of URCARE Registry)

Line	All	Adalimumab / Biosimilars	Infliximab / Biosimilars	Ustekinumab	Golimumab	Guselkumab	Infliximab / Biosimilars	Infliximab / Biosimilars	Satizimab	Risankizumab	Ustekinumab	Vedolizumab
First line	713	119 (16,7%)	132 (18,5%)	0	0	0	119 (20,9%)	63 (8,8%)	0 (0,1%)	0	122 (17,1%)	127 (17,8%)
Second line	267	17 (6,4%)	28 (10,5%)	0	0	0	27 (21,3%)	7 (2,6%)	0 (0,4%)	0	139 (51,7%)	27 (10,1%)
Third line	116	2 (1,7%)	3 (2,6%)	0	0	0	18 (15,5%)	2 (1,7%)	0	0	68 (58,6%)	23 (19,8%)
Fourth line	50	3 (6,0%)	4 (8,0%)	0	0	0	7 (14,0%)	1 (2,0%)	0	0	24 (48,0%)	11 (22,0%)
Fifth line	14	1 (7,1%)	0	0	0	3 (21,4%)	3 (21,4%)	0	0	0	4 (28,6%)	3 (21,4%)
Sixth line	2	1 (50,0%)	0	0	0	0	0	0	0	0	0	1 (50,0%)
Sevent line	1	0	0	0	0	0	0	0	0	0	0	1 (100%)
Total*	1166	143 (12,3%)	167 (14,4%)	0	0	3 (0,3%)	234 (20,1%)	73 (6,3%)	0 (0,2%)	0	348 (29,9%)	193 (16,6%)

18

Ulcerozni kolitis: razmerje originator/biosimilar Slovenija
– podatki iz registra za leto 2023


Utilisation of advanced treatments in inflammatory bowel disease in Slovenia – national report from URCARE Registry for the year 2023

Uporaba naprednih zdravil pri bolnikih s kronično vnetno črevesno boleznijo v Sloveniji – nacionalni podatki iz URCARE registra za leto 2023

Table 5. Number of prescriptions (treatment episodes) in respective lines of therapy for ulcerative colitis (from inception of URCARE Registry)

Line	All	Adalimumab/ biosimilars	Adalimumab/ Humira	Certolizumab	Golimumab	Guselkumab	Infliximab/ biosimilars	Infliximab/ Remicade	Natalizumab	Risankizumab	Ustekinumab	Yescolizumab
First line	811	31 (3,8%)	59 (7,3%)	0	75 (9,2%)	0	191 (23,6%)	97 (12,0%)	0	0	55 (6,8%)	303 (37,4%)
Second line	327	13 (4,0%)	43 (13,1%)	0	13 (4,0%)	0	78 (23,9%)	25 (7,6%)	1 (0,3%)	39 (11,9%)	115 (35,2%)	
Third line	151	4 (2,6%)	0	0	4 (2,6%)	0	39 (19,9%)	4 (2,6%)	3 (2,0%)	0	47 (31,1%)	51 (33,8%)
Fourth line	40	1 (2,5%)	0 (0,0%)	0	1 (2,5%)	0	7 (17,5%)	3 (7,5%)	0	0	19 (47,5%)	7 (17,5%)
Fifth line	11	0	0	0	2 (18,2%)	0	1 (9,1%)	4 (36,4%)	0	0	3 (27,3%)	1 (9,1%)
Sixth line	2	0	1 (50,0%)	0	0	0	0	0	0	0	1 (50,0%)	0
Seventh line	0	0	0	0	0	0	0	0	0	0	0	0
Total*	1342	49 (3,7%)	111 (8,3%)	0	95 (7,1%)	0	307 (22,9%)	134 (10,0%)	4 (0,3%)	39 (2,9%)	164 (12,2%)	478 (35,6%)

19



20

IBD team LJUBLJANA

- 5 gastroenterology consultants
- 2-4 trainees
- 3 IBD nurses
- 2 study coordinators

21

Hvala za pozornost



17. mednarodni simpozij / 17th International Symposium,
Ljubljana, 5. november 2024

22

22

Podobna biološka zdravila: izkušnje s področja onkologije

Biosimilars: Experience in Oncology

Simona Borštnar

Onkološki Inštitut Ljubljana

Povzetek

Biološka zdravila kot so tarčna monoklonska protitelesa so v zadnjih dveh desetletjih postala ena od ključnih zdravil v onkologiji. Razvoj podobnih bioloških zdravil izhaja iz visokih stroškov bioloških zdravil. Podobna biološka zdravila, ki so po zgradbi in delovanju podobna referenčnim biološkim zdravilom so za bolnike enako učinkovita in varna, vendar cenejša. Imajo ključno vlogo pri spodbujanju konkurence v farmacevtski industriji in zagotavljanju dostopa bolnikov do osnovnih zdravil.

V onkologiji so trenutno na voljo tri podobna biološka zdravila iz skupine monoklonskih protiteles: trastuzumab, rituksimab in bevacuzimab. Od leta 2019 do sedaj se je skupen strošek za ta zdravila na Onkološkem inštitutu v Ljubljani, ki pokriva zdravljenje več kot 70% vseh slovenskih bolnikov z rakom, znižal za več kot trikrat z okoli 13 mio EUR na okoli 4 mio EUR. Prihodnost podobnih bioloških zdravil pri zdravljenju raka veliko obeta pri širjenju indikacij, saj bo več podobnih bioloških zdravil prejelo regulativno odobritev, njihova uporaba pa se bo verjetno razširila na širši spekter vrst raka in terapevtskih indikacij.

Abstract

Biological drugs, such as targeted monoclonal antibodies, have become one of the key treatments in oncology over the past two decades. The development of biosimilar drugs stems from the high costs of biological drugs. Biosimilar drugs, which are similar in structure and function to reference biological drugs, are equally effective and safe for patients but are less expensive. They play a crucial role in promoting competition in the pharmaceutical industry and ensuring patient access to essential medicines.

In oncology, there are currently three biosimilar drugs available from the monoclonal antibody group: trastuzumab, rituximab, and bevacizumab. From 2019 to the present, the total cost for these drugs at the Oncology Institute in Ljubljana, which covers the treatment of more than 70% of all Slovenian cancer patients, has decreased more than threefold from around 13 million EUR to around 4 million EUR. The future of biosimilar drugs in cancer treatment is very promising in terms of expanding indications, as more biosimilar drugs will receive regulatory approval, and their use is likely to extend to a broader range of cancer types and therapeutic indications.



ONKOLOŠKI INŠTITUT
INSTITUTE OF ONCOLOGY
LJUBLJANA

Podobna biološka zdravila: izkušnje s področja onkologije

Doc.dr. Simona Borštnar, dr. med
Oddelek za internistično onkologijo
Onkološki inštitut Ljubljana

Ljubljana, 5.11.2024

1

Razkritje

Avtorski honorarji za predavanja:
AstraZeneca, Eli Lilly, Lek, MSD, Novartis, Pfizer, Roche, Swixx Biopharma

Svetovni odbori in strokovna mnenja:
AstraZeneca, Gilead, Eli Lilly, MSD, Merck, Novartis, Pfizer, Roche, Swixx Biopharma



2

Vsebina


- Pregled naraščajočih stroškov za zdravila v onkologiji
- Biološka zdravila v onkologiji
- Biološka podobna zdravila v onkologiji
- Znižanje stroškov zdravljenja z uporabo bioloških podobnih zdravil v onkologiji



3

Napoved rasti za 20 največjih terapevtskih področij

Global historic and forecast growth for top 20 therapy areas




4

Porast stroškov po posameznih lokalizacijah raka do leta 2028

Six of the top 10 tumors have double-digit spending growth, all areas of significant numbers of breakthrough new medicines

Exhibit 54: Global oncology spending by tumor US\$Bn, 2019–2028




5

Letna rast stroškov za onkološka zdravila do leta 2028

Cancer medicine spending rose to \$223Bn globally in 2023 and is expected to reach \$409Bn by 2028


Exhibit 51: Oncology spending by region, US\$Bn




6




7



8




9



10



11



12

Kaj omogoča uvajanje podobnih bioloških zdravil


-  Dodatne terapevtske možnosti
-  Širšo dostopnost učinkovitih bioloških zdravil
-  Znižanje stroškov za biološka zdravila
-  Prihranke v zdravstveni blagajni

13

Kaj je pomembno v klinični praksi

-  **Odobritev s strani regulatornih agencij** (dokazana klinična učinkovitost in varnost zdravila)
-  **Zasnova raziskave:** dovolj občutljiva populacija, dobro izbran cilj raziskave, podatki o preklopu
-  **Zdravilo na voljo** v bolnišnični lekarni
 - zagotovljena zaloga
 - na voljo vse farmacevtske oblike
-  **Zagotovljena sledljivost zdravila** (zapis z lasniškim imenom v CIPRO in vzpostavljena farmakovigilanca)
-  **Čas prisotnosti proizvajalca** (proizvodni proces) na tržišču

14




15

Porast porabe podobnih bioloških zdravil v ZDA, Evropi in na Japonskem

Oncology biosimilar uptake has been greater than 50% across major markets and biosimilars saved payers over \$7Bn in 2023

Exhibit S3: Average oncology biosimilar uptake and estimated biosimilar savings in U.S., EU4+UK, and Japan, US\$Bn




16


Odobrene indikacije podobnih bioloških zdravil- monoklonskih protiteles v onkologiji

Oncology approved indications


NAMES		CLASSIFICATION										REGISTRATION										DESIGN																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																				
MOLEKULE	PRODUCT	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2423	2424	2425	2426	2427	2428	2429	2430	2431	2432	2433	2434	2435	2436	2437	2438	2439	2440	2441	2442	2443	2444	2445	2446	2447	2448	2449	2450	2451	2452	2453	2454	2455	2456	2457	2458	2459	2460	2461	2462	2463	2464	2465	2466	2467	2468	2469	2470	2471	2472	2473	2474	2475	2476	2477	2478	2479	2480	2481	2482	2483	2484	2485	2486	2487	2488	2489	2490	2491	2492	2493	2494	2495	2496	2497	2498	2499	2500	2501	2502	2503	2504	2505	2506	2507	2508	2509	2510	2511	2512	2513	2514	2515	2516	2517	2518	2519	2520	2521	2522	2523	2524	2525	2526	2527	2528	2529	2530	2531	2532	2533	2534	2535	2536	2537	2538	2539	2540	2541	2542	2543	2544	2545	2546	2547	2548	2549	2550	2551	2552	2553	2554	2555	2556	2557	2558	2559	2560	2561	2562	2563	2564	2565	2566	2567	2568	2569	2570	2571	2572	2573	2574	2575	2576	2577	2578	2579	2580	2581	2582	2583	2584	2585	2586	2587	2588	2589	2590	2591	2592	2593	2594	2595	2596	2597	2598	2599	2600	2601	2602	2603	2604	2605	2606	2607	2608	2609	2610	2611	2612	2613	2614	2615	2616	2617	2618	2619	2620	2621	2622	2623	2624	2625	2626	2627	2628	2629	2630	2631	2632	2633	2634	2635	2636	2637	2638	2639	2640	2641	2642	2643	2644	2645	2646	2647	2648	2649	2650	2651	2652	2653	2654	2655	2656	2657	2658	2659	2660	2661	2662	2663	2664	2665	2666	2667	2668	2669	2670	2671	2672	2673	2674	2675	2676	2677	2678	2679	2680	2681	2682	2683	2684	2685	2686	2687	2688	2689	2690	2691	2692	2693	2694	2695	2696	2697	2698	2699	2700	2701	2702	2703	2704	2705	2706	2707	2708	2709	2710	2711	2712	2713	2714	2715	2716	2717	2718	2719	2720	2721	2722	2723	2724	2725	2726	2727	2728	2729	2730	2731	2732	2733	2734	2735	2736	2737	2738	2739	2740	2741	2742	2743	2744	2745	2746	2747	2748	2749	2750	2751	2752	2753	2754	2755	2756	2757	2758	2759	2760	2761	2762	2763	2764	2765	2766	2767	2768	2769	2770	2771	2772	2773	2774	2775	2776	2777	2778	2779	2780	2781	2782	2783	2784	2785	2786	2787	2788	2789	2790	2791	2792	2793	2794	2795	2796	2797	2798	2799	2800	2801	2802	2803	2804	2805	2806	2807	2808	2809	2810	2811	2812	2813	2814	2815	2816	2817	2818	2819	2820	2821	2822	2823	2824	2825	2826	2827	2828	2829	2830	2831	2832	2833	2834	2835	2836	2837	2838	2839	2840	2841	2842	2843	2844	2845	2846	2847	2848	2849	2850	2851	2852	2853	2854	2855	2856	2857	2858	2859	2860	2861	2862	2863	2864	2865	2866	2867	2868	2869	2870	2871	2872	2873	2874	2875	2876	2877	2878	2879	2880	2881	2882	2883	2884	2885	2886	2887	2888	2889	2890	2891	2892	2893	2894	2895	2896	2897	2898	2899	2900	2901	2902	2903	2904	2905	2906	2907	2908	2909	2910	2911	2912	2913	2914	2915	2916	2917	2918	2919	2920	2921	2922	2923	2924	2925	2926	2927	2928	2929	2930	2931	2932	2933	2934	2935	2936	2937	2938	2939	2940	2941	2942	2943	2944	2945	2946	2947	2948	2949	2950	2951	2952	2953	2954	2955	2956	2957	2958	2959	2960	2961	2962	2963	2964	2965	2966	2967	2968	2969	2970	2971	2972	2973	2974	2975	2976	2977	2978	2979	2980	2981	2982	2983	2984	2985	2986	2987	2988	2989	2990	2991	2992	2993	2994	2995	2996	2997	2998	2999	3000	3001	3002	3003	3004	3005	3006	3007	3008	3009	3010	3011	3012	3013	3014	3015	3016	3017	3018	3019	3020	3021	3022	3023	3024	3025	3026	3027	3028	3029	3030	3031	3032	3033	3034	3035	3036	3037	3038	3039	3040	3041	3042	3043	3044	3045	3046	3047	3048	3049	3050	3051	3052	3053	3054	3055	3056	3057	3058	3059	3060	3061	3062	3063	3064	3065	3066	3067	3068	3069	3070	3071	3072	3073	3074	3075	3076	3077	3078	3079	3080	3081	3082	3083	3084	3085	3086	3087	3088	3089	3090	3091	3092	3093	3094	3095	3096	3097	3098	3099	3100	3101	3102	3103	3104	3105	3106	3107	3108	3109	3110	3111	3112	3113	3114	3115	3116	3117	3118	3119	3120	3121	3122	3123	3124	3125	3126	3127	3128	3129	3130	3131	3132	3133	3134	3135	3136	3137	3138	3139	3140	3141	3142	3143	3144	3145	3146	3147	3148	3149	3150	3151	3152	3153	3154	3155	3156	3157	3158	3159	3160	3161	3162	3163	3164	3165	3166	3167	3168	3169	3170	3171	3172	3173	3174	3175	3176	3177	3178	3179	3180	3181	3182	3183	3184	3185	3186	3187	3188	3189	3190	3191	3192	3193	3194	3195	3196	3197	3198	3199	3200	3201	3202	3203	3204	3205	3206	3207	3208	3209	3210	3211	3212	3213	3214	3215	3216	3217	3218	3219	3220	3221	3222	3223	3224	3225	3226	3227	3228	3229	3230	3231	3232	3233	3234	3235	3236	3237	3238	3239	3240	3241	3242	3243	3244	3245	3246	3247	3248	3249	3250	3251	3252	3253	3254	3255	3256	3257	3258	3259	3260	3261	3262	3263	3264	3265	3266	3267	3268	3269	3270	3271	3272	3273	3274	3275	3276	3277	3278	3279	3280	3281	3282	3283	3284	3285	3286	3287	3288	3289	3290	3291	3292	3293	3294	3295	3296	3297	3298	3299	3300	3301	3302	3303	3304	3305	3306	3307	3308	3309	3310	3311	3312	3313	3314	3315	3316	3317	3318	3319	3320	3321	3322	3323	3324	3325	3326	3327	3328	3329	3330	3331	3332	3333	3334	3335	3336	3337	3338	3339	3340	3341	3342	3343	3344	3345	3346	3347	3348	3349	3350	3351	3352	3353	3354	3355	3356	3357	3358	3359	3360	3361	3362	3363	3364	3365	3366	3367	3368	3369	3370	3371	3372	3373	3374	3375	3376	3377	3378	3379	3380	3381	3382	3383	3384</



19



20



21

ZAKLJUČEK

- Podobna biološka zdravila vse bolj postajajo nepogrešljiv del zdravstvene oskrbe, saj znižujejo cene in povečujejo dostopnost zdravil.
- To še posebej velja za onkološko zdravljenje, kjer podobna biološka zdravila pomagajo razširiti dostop do oskrbe bolnikov z rakom tudi v ekonomsko manj močnih državah.



Podobna biološka zdravila: izkušnje s področja revmatologije

Biosimilars: Experiences in Rheumatology

Iztok Holc

Univerzitetni klinični Center Maribor, Oddelek za revmatologijo

Povzetek

Podobno biološko zdravilo (PBZ) je biološko zdravilo, za katerega je pridobljeno dovoljenje za promet po preteku patentne zaščite originalnega referenčnega zdravila. Prednosti PBZ so: nižja cena zdravil, varčevanje denarja v zdravstvu in lažja dostopnost bioloških zdravil. Izzivi na katere moramo biti pozorni so: ekstrapolacija indikacij, imunogenost in zamenljivost. Raziskave podpirajo prehod z originatorjev na PBZ, a svetujejo previdnost.

V prispevku bom predstavil rezultate prehoda iz originatorja infliksimaba na PBZ na Oddelku za revmatologijo UKC Maribor.

Abstract

A biosimilar medicine (BSM) is a biological medicine for which marketing authorization is granted after the patent protection of the original reference medicine has expired. The benefits of BSMs include lower drug prices, cost savings in the healthcare system, and better access to biological medicines. Challenges we must be aware of include extrapolation of indications, immunogenicity, and interchangeability. Research supports the transition from originators to BSMs but advises caution. In my lecture, I will present the results of the switch from the originator drug infliximab to a BSM in the Department of Rheumatology University Medical Centre Maribor.



Zamenljivost bioloških in podobnih bioloških zdravil, izkušnje z zamenjavo infliksimaba

UKC Univerzitetni klinični center
MARIBOR Maribor

IZTOK HOLC
ODDELEK ZA REVMATOLOGIJO
KLINIKA ZA INTERNO MEDICINO
UKC MARIBOR

1

Podobno biološko zdravilo (PBZ)


Je biološko zdravilo, za katerega je pridobljeno dovoljenje za promet po preteku patenske zaščite originalnega referenčnega zdravila

NI identično (struktura proteina, proizvodni proces, celična linija,...).

JE primerljivo glede na izkazano učinkovitost, varnost in kakovost.

DOKAZANO s kliničnimi preskušnji in z raziskavami bioekvivalence.

EMA je prvič sprejela smernice glede podobnih bioloških zdravil leta 2005, posodobitev leta 2014.




Vir: Similar Genovisology Biosimilar Swiss Newsletter

2

Slika 3. Primer variabilnosti med podobnim biološkim in referenčnim zdravilom


Variabilnost (osredotočeno z rumeno) med podobnim biološkim in referenčnim zdravilom je primerljiva variabilnosti med različnimi serijami določenega biološkega zdravila (slika 2). Dovoljena je lahko manjša variabilnost, npr. pri glikozilaciji (ki jo ponazarjajo majhni trikotniki), medtem ko sta zaporedje aminokislin (brižgi) in biološka aktivnost enaka.



Referenčno zdravilo Podobno biološko zdravilo

Podobna biološka zdravila v EU
Informacije proizvajalca in zdravilnega oddelka

3



4

Terminologija

Zamenljivost (angl. interchangeability) = praksa zamenjave enega zdravila za drugega s pričakovano enakim kliničnim rezultatom pri enaki klinični uporabi pri kateremkoli bolniku s strinjanjem predpisovalca

Substitucija = praksa zamenjave zdravila za drugo zamenljivo zdravilo na lekarniškem nivoju, brez konzultacije predpisovalca

Switching = odločitev lečečega zdravnika o zamenjavi zdravila za drugo zdravilo z enakim terapevtskim ciljem pri zdravljene bolniku; tudi zamenjava originalnega biološkega zdravila s PBZ

- **Cross-switching** = zamenjava enega PBZ z drugim PBZ oz. navzkrižna zamenjava
- **Reverse-switching** = zamenjava PBZ z originalnim biološkim zdravilom oz. povratna zamenjava
- **Multiple-switching** = večkratna zamenjava

5

PBZ za zdravljenje vnetnih revmatskih bolezni

INFLIKSIMAB (REMICADE®) 2013 Remsima® (Celtrion/Oktal Pharma) Inflectra® (Pfizer) - Filixab® (Samsung Bioepis/Biogen) Zessly® (Sandoz/Lek)	ADALIMUMAB (HUMIRA®) 2018 Amgevita® (Amgen) Imraldi® (Samsung Bioepis/Biogen) - Hulio® (Regeneron/Viatris) Hyrimoz® (Sandoz/Lek) Idacio® (Fresenius Kabi/Medias) Hukyndra® (Stada) Yuflyma® (Celtrion/Oktal Pharma)	RITUXIMAB (MABTHERA®) Rixathon® (Sandoz/Lek) Truxima® (Celtrion) Blitzima® (Celtrion)
ETANERCEPT (ENBREL®) Benepali® (Samsung) Erelzi® (Sandoz)		TOCILIZUMAB (ROACTEMRA®) Tyenne® (Fresenius Kabi) Tofidence® (Biogen Netherlands)

*Zdravila so vse zdravila z lastnimi imeni, ki so dostopna na www.gov.si (seznam zdravil 2. izbora, 1. izbora)

6

Prednosti PBZ

1. Nižja cena zdravil

- V EU cca. 30% (do 69% na Norveškem);
- razlika napram generičnim zdravilom, kjer je cena nižja za 70-80%

2. Varčevanje denarja v zdravstvu

- Znižanje stroškov za raziskave in razvoj zdravil
- Konkurenca
- Enostavnejša pot odobritve zdravila
- Skupaj v EU in ZDA bi lahko v 5 letih privarčevali od 56-112 milijard \$

3. Lažja dostopnost bioloških zdravil

- Več bolnikov zdravljenih z biološkim zdravilom (na Češkem leta 2014 zdravljenih 1000 bolnikov več kot leta 2013)
- Bolniki lahko biološko zdravilo dobijo prej v poteku svoje bolezni
- Več izbire med biološkimi zdravili



7

Izzivi PBZ

1. Ekstrapolacija indikacij

- Klinične raziskave pri RA in axSpA, tudi pri KVČB
- Specifična distribucija v tkivih, različna učinkovitost v različnih tkivih
- Razlike v ADCC = antibody-dependent cell-mediated cytotoxicity
- Razlike v populacijah bolnikov (starost, pridružene bolezni, druga zdravila,...)
- Razlike v odmerkih, načinu aplikacije

2. Imunogenost

- Nepredvidljivo tveganje za imunogenost zaradi razlik med molekulami
- Pojav protiteles proti zdravilu – alergije, izguba učinka
- Vplivi: proizvodnja, post-translacijske modifikacije, pot aplikacije, značilnosti bolnika,...

3. Zamenljivost

- Switching; že dokazi o varnosti iz kliničnih observacijskih raziskav
- Cross-switching; že objave o zamenjavi med PBZ
- Reverse-switching; že objave o menjavi s PBZ na originalni IFX
- Multiple-switching; že objave o do 3x zamenjavah



Podatki se nanašajo na raziskave na naslednjih straneh.

8

Podatki o zamenljivosti

ENKRATNA ZAMENJAVA

RCT :

- NOR-SWITCH (IFX za KVČB)
- REFLECTIONS (IFX za RA)
- ADMYRA (ADA za RA)

Podatki iz klinične prakse

- IFX in ADA
- Pri KVČB in revmatoloških vnetnih boleznih

VEČKRATNA ZAMENJAVA (DO 3X)

Podatki iz klinične prakse

- Originalni IFX – PBZ 1. – PBZ 2.
- PBZ 1. – PBZ 2.
- IFX in ADA
- Pri KVČB in revmatoloških vnetnih boleznih

Sistematični pregled raziskav

RCT (randomized controlled trial), IFX (infliximab), ADA (adalimumab)

9

Sistematična analiza

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies

Wolfgang Dittmann¹, Sarah Huchbach², Wolfgang Bodenmüller³, Toni K. Kienle⁴, Silvio Danneberg⁵, Andrea Stawell⁶

- Zamenjave med PBZ (IFX, ADA, ETA, RTX)
- 3657 bolnikov (KVČB, RA, PsA, SpA,...)
- Vse raziskave so bile opazovalne narave; RCT
- Študije so bile heterogene glede na velikosti, zasnovi in končne cilje.

Ni bilo zaznanih zmanjšanja učinkovitosti ali povečanja neželenih učinkov po zamenjavi med PBZ

IFX = infliximab, ADA = adalimumab, ETA = etanercept, RTX = rituximab

13

Skupna izjava EMA-HMA o medsebojni zamenljivosti bioloških zdravil (september 2022)

Podobna biološka zdravila, odobrena v EU, so medsebojno zamenljiva.

Zamenljivost se nanaša na možnost zamenjave enega zdravila za drugo zdravilo, ki naj bi imelo enak klinični učinek.

HMA in EMA menita, da je podoben biološki izdelek, ko je odobren v EU, medsebojno zamenljiv, kar pomeni, da se lahko uporablja namesto referenčnega izdelka (ali obratno) ali pa se en podoben biološki izdelek nadomesti z drugim podobnim biološkim izdelkom istega referenčnega izdelka. Zamenjava se lahko izvede le po skrbni preučitvi odobrenih pogojev uporabe (tj. po posvetovanju z najnovejšimi informacijami o zdravilu).

Odlčitve o tem, kako izvajati medsebojno zamenljivost z zamenjavo (pod nadzorom predpisovalca), in/ali nadomestitvijo (praksa izdaje enega zdravila namesto drugega zdravila brez posvetovanja z predpisovalcem, kot je samodejna zamenjava na ravni lekarne), niso v pristojnosti agencije EMA in jih upravljajo posamezne države članice.

14

Nocebo učinek

Bolnikova negativna pričakovanja ob zamenjavi za PBZ lahko vodijo v neuspešnost zdravljenja.

Nocebo učinek je moč zmanjšati z **individualno prilagojenim izobraževanjem bolnikov**, pri čemer je odnos med bolnikom in njegovimi zdravstvenimi delavci priznan kot ključni dejavnik za sprejemanje podobnih bioloških zdravil.


NOCE-BIO konsenzusna skupina je priporočila multidisciplinarna prizadevanja za zmanjšanje učinka nocebo pri bolnikih s KVČB, ki se zdravijo s PBZ, z ukrepi za zdravnike, medicinske sestre, psihologe in farmacevte.

Edukacija!


15



16




17



18

Diagnoze



19

Trajanje zdravljenja

	Povprečje (m)	Min (m)	Max (m)
Trajanje zdravljenja Remicade*	127.8	8.93	197.17
Trajanje zdravljenja Zessly*	11.13	7.9	12.6




20

Zdravljenje pred infliximabom


- ❖ 1 bolnica – etanercept
- ❖ 1 bolnik - adalimumab in etanercept
- ❖ 1 bolnica - adalimumab
- ❖ 1 bolnik - etanercept in adalimumab




21




22




23




24



25



26



27

Prekinitev terapije z Zessly-jem

- Neučinkovitost – 2 bolnici
- Prehod na RTX zaradi pljučne prizadetosti



28

Neželeni učinki

- pri Zesly-ju nismo opazovali neželenih učinkov




29

Zaključek

- ♦ Od odobritve prvega podobnega biološkega zdravila v EU je v > 15 letih že > 400 milijonov bolnikovih let izkušenj.
- ♦ Pomembno je skrbno (post-marketingško) sledenje učinkovitosti in varnosti.
- ♦ Edukacija uporabnikov je potrebna.
- ♦ Nepristransko obveščanje o koristih in ev. izzivih podobnih bioloških zdravil.
- ♦ Podatki o imunogenosti v luči različnih oblik zamenjevanja oz. „switching-a“.
- ♦ Potreben je konsenz zainteresiranih deležnikov (bolniki, medicinsko osebje, plačnik, politika...)
- ♦ V naši kohorti so PSZ enako učinkovita in varna kot originator.

30



31

5 pravil za uspešno uvedbo podobnih bioloških zdravil

The 5 rules for successful introduction of biosimilars

Arnold G. Vulto

Erasmus University Medical Center, Dept. Of Hospital Pharmacy, Rotterdam, The Netherlands

Povzetek

Za uspešno uvedbo biološko podobnega zdravila ni ene same rešitve. Obstaja veliko spremenljivk, kot so nacionalni zdravstveni sistem, pravila o povračilih, status zavarovanja, odnos zdravnikov, zaupanje pacientov, kulturne razlike itd. Naše raziskave na tem področju so pokazale pet skupnih dejavnikov pri uspešnih uvedbah biološko podobnih zdravil:

- Pristop več deležnikov: v proces odločanja in izvedbe uvedbe biološko podobnega zdravila v bolnišnico vključite vse deležnike v zdravstvenem sistemu (predpisovalce, medicinske sestre, vodstvo, farmacevte itd.).
- Komunicirajte s principom enotnega glasu (vsi, ki so vključeni v proces uvajanja podobnega biološkega zdravila, sporočajo enako) za preprečitev lažnih nocebo učinkov.
- Obvestite pacienta, da se bo zdravljenje začelo/nadaljevalo z enako varno in učinkovito alternativo.
- Zdravstvene delavce nagradite za njihov čas in trud, ki ga vložijo v uvedbo spremembe, z neko obliko finančnega nadomestila.
- Transparentno poročajte, kaj se bo zgodilo s prihranki in kako bodo uporabljeni/ponovno vloženi v zdravstveni sistem.

Če so biološko podobna zdravila v določenih primerih manj uspešna, je običajno eden ali več teh dejavnikov odsoten ali slabo izveden.

Na Nizozemskem so bila ta načela vključena v t. i. Orodjarno za biološko podobna zdravila – uradno podprto s strani Združenja nizozemskih bolnišničnih farmacevtov in Federacije vseh združenj medicinskih specialistov. Orodjarna med drugim vključuje diagram poteka, odločitvena drevesa in vzorčna pisma. Ta močan kolegialen pristop je omogočil, da so se v bolnišnicah pri delu izognili mnogim razpravam in se je izkazal za zelo učinkovit pri sprejemanju biološko podobnih zdravil.

Referenca:

<https://gbiomed.kuleuven.be/english/research/50000715/52577001/mabel/Keyinsights>

Abstract

There is no single solution for a successful introduction of a biosimilar. There are many variables, like the national health system, reimbursement rules, insurance status, physicians'

attitude, patients trust, cultural differences etc. Our research in this area has indicated 5 common denominators in successful biosimilar adoptions:

Multistakeholder approach: involve everybody (prescribers, nurses, management, pharmacists etc.) in the health system in the decision and execution process of launching a biosimilar in a hospital.

- Communicate with a one-voice principle to avoid false nocebo-effects.
- Inform the patient that the treatment will be initiated / continued with an equally safe and effective alternative.
- Compensate the healthcare professionals (HCPs) for their time and effort to make the change possible with a form of gain sharing.
- Report transparently what will happen with the savings and how they will be used / reinvested in the healthcare system.
- If biosimilars are less succesful in certain situations, usually one or more of these factors are absent or where badly implemented.

In The Netherlands these principles were included in a Biosimilar Toolbox – officially endorsed by the Dutch Hospital Pharmacists Association and the Federation of all Medical Specialist Associations. It includes amongst others a flow diagram, decision trees and example letters. This powerful collegial approach has avoided a lot of discussion on the workflow in the hospital and appeared very powerful in the acceptance of biosimilars.

Reference:

<https://gbiomed.kuleuven.be/english/research/50000715/52577001/mabel/Keyinsights>

VuPEC
Vulto Pharma Education & Consultancy

Biosimilar Symposium Slovenian Pharmaceutical Society, Hospital Pharmacy Section
Ljubljana, November 5, 2024

Critical Factors for the successful introduction of biosimilars

Prof. Dr. Arnold G. Vulto F.C.P.
Hospital Pharmacist n.p. / Pharmacologist
ErasmusMC Rotterdam / KU Leuven Belgium
a.vulto@gmail.com

© VuPEC Handout 24k01

Erasmus MC

KU LEUVEN

Agenda

- *This presentation contains a lot of information for home study*
- No market is the same, no single best practice
 - Adjust policies to local situation and conditions
- Key Factors for the successful implementation of biosimilars
- A Biosimilar Toolbox
 - a practical example from The Netherlands
- Lessons Learned and Take Home Message

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

No single market is the same

- Although the value proposition of biosimilars is rather similar to that of generics, the barriers are higher.
- Markets vary, as do health systems, guidelines, indications, attitudes of health care professionals (HCP's) and in general the social trust in a country.
- As a result, there is no single best practice recipe for biosimilar introductions.

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

Not all biosimilar markets are equal: Three archetypes of maturity phase and their characteristics in Europe

	PRIMARY OPPORTUNITIES	MAIN BIOSIMILAR BENEFIT
INVEST No or little access to reference biologics because of their high cost	Offer the first opportunity for treatment with biologics	Lower-cost biosimilars allow markets to provide access to biologics that were previously too costly
EXPAND Some access to reference biologics but some patients/subpopulations do not qualify for reimbursement or have only limited access	Expand access to biologics to a greater number of patients	Cost savings from biosimilars allow expanded access to biologic therapies, treating more patients
HARVEST Access to biologics is high and covers reference biologics and biosimilars	Appropriately recycle cost savings Sustain biosimilar competition	Competition of manufacturers for stable, lower-cost supply of biologics while driving innovation

• Mestre-Ferrandiz J et al. Expert Rev Pharmacoecon Outcomes Res 2024; 24:237–250.
 • Available at:
<https://www.tandfonline.com/doi/full/10.1080/14737167.2023.2297926>;





• Mestre-Ferrandiz J et al. Expert Rev Pharmacoecon Outcomes Res 2024; 24:509–519.
 • Available at:
<https://www.tandfonline.com/doi/full/10.1080/14737167.2024.2310684>.

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

Example of different indications

- A failing treatment for a rheumatoid arthritis patient has different consequences than for an colitis ulcerosa patient.
- In RA there are many follow-up treatments, for UC it could mean quite dramatic surgery.
- That's why we see more hesitation among gastroenterologists who have little knowledge about biosimilars.

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024



Key principles to support successful biosimilar implementation in clinical care

- Apply a multi-stakeholder approach → involving and educating relevant HCPs about biosimilars
- Communicate via a one-voice principle → avoiding the nocebo effect
- Inform the patient → the treatment is initiated/continued with an equally safe and effective alternative
- Compensate HCPs for the time and effort associated with a switch → gain sharing concept
- Report transparently about:
 1. Savings generated from biosimilar market introduction
 2. The allocation of savings within the healthcare system

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024 10

1. Multi-stakeholder approach

- Involve and inform all relevant stakeholders in biosimilar policies; align their interests
 - Healthcare officials, insurance companies (invest in sustainability)
 - Hospital management (biosimilars are no generics!)
 - Medical professionals, (hospital) pharmacists, nurses
 - Patients: has your hospital a patient-council? Educate them

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024 11



2. Apply the one-voice principle

- Avoid the nocebo-effect


Pharmaceutical Medicine
<https://doi.org/10.1007/s40200-024-00541-y>

SYSTEMATIC REVIEW

Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review
 Elif Car¹, Yannick Vandeplass¹, Teresa Barcina Lacosta¹, Steven Simoons¹, Isabelle Huys¹, Arnold G. Vulto^{1,2}, Liese Barbier¹

Accepted: 26 September 2024
 © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024




**In Press
October 2024**



Are you familiar with the nocebo-effect?

- The nocebo effect (in Latin “I shall harm”) is defined as the occurrence of negative expectations about a treatment or a change in treatment which can lead to worsened symptoms (i.e., lower treatment efficacy) or adverse events (AEs) and cannot be attributed to the pharmacologic action of a treatment itself
- The nocebo effect is highly relevant to use of biosimilars including switching from originator to biosimilars due to misconceptions and lack of confidence among health care providers and patients about biosimilars

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024






3. Inform the patient properly

- Treatment will be continued (or initiated) with a different brand with equal efficacy and safety
- Keep a positive tone: this is good for all of us
- Taylor information to the attitude and level of understanding of a patient
- Avoid random searching the internet
- Keep it “small”

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024



4. Compensate professionals

- HCP's invest a lot of time and effort to make this happen
- Appreciate those efforts and reward them
 - Design gain sharing schemes with your management

bioRxiv
<https://doi.org/10.1101/40219-022-09523-2>

ORIGINAL RESEARCH ARTICLE

Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe

Teresa Barcina Lacosta¹ · Arnold G. Vulto² · Adina Turcu-Stoliciu³ · Isabelle Huys⁴ · Steven Simoons⁵

Accepted: 23 February 2022
© The Author(s) 2022



5. Report benefits transparently

- What has been achieved?
 - Like: cost reduction, more patients treated, new services, more staff
- Where have the savings gone?
 - Reinvested in healthcare, benefitting patients?


17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

Biosimilar Toolbox: A practical example from The Netherlands



- Introduction of biosimilars follows the rules of “change management”: inform and partner with everybody involved
- Engage with your medical specialist associations
 - Align your objectives and team up together
 - This avoids needless discussions on the hospital floor
- Together we have built a “biosimilar toolbox”

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024




Dutch Hospital Pharmacists Association and Dutch Federation of Medical Specialists

NVZA Toolbox Biosimilars

Deze praktische handleiding voor succesvolle implementatie van biosimilars is de medisch-specialistische zorg.

- **Toolbox biosimilars (2017)**
- A practical guide for succesful implementation
 - Scientific background, definitions and position papers (e.g. MEB)
 - New patients, existing patients
 - Implementation: task force and roadmap
 - Policies for transitioning
 - Information materials, letters


MEB, Medicines Evaluation Board



Lessons learned:

Communication, communication and communication

- Multistakeholder approach
 - Involve all those relevant: prescribers, pharmacists, patients, nurses, procurement department and hospital managers
 - Shared decision making
- Speak with one voice
 - Avoid distorting information
 - Beware of attribution and nocebo-effects
- Make selection process transparent for all
 - Advantages and disadvantages
 - Who will gain (preferably: gain sharing)



Take-home message

- Implementation of a biosimilar policy should be managed as a project
 - Multidisciplinary, One Voice, Shared decision making, Gain sharing
 - Specialised nurses involved in educating patients
 - Engage a patient representative in your biosimilar policy
 - Organise disease-specific patient information sessions on biosimilars
 - Run as pharmacy special biosimilar sessions with all relevant medical departments
- The Dutch NVZA / Federation Medical Specialists Toolbox based on "best practice"
- Procurement is a three-party process:
 - Medical stakeholder, Specialist pharmaceuticals, Procurement/contract specialist

Be transparent, educate and communicate, communicate, communicate
Hospital pharmacists play an essential role in acceptance and implementation of biosimilars.
Take your responsibility!

Izkušnje bolnišničnega farmacevta z implementacijo podobnih bioloških zdravil v klinični praksi

The experience of a hospital pharmacist with the implementation of biosimilars in clinical practice

Tomislav Laptoš

Univerzitetni klinični center Ljubljana, Lekarna

Povzetek

Uvedba podobnih bioloških zdravil v klinično prakso je prinesla v bolnišnično okolje precejšnje spremembe. V prvi fazi je bilo na strani (predvsem predpisovalcev) zaznati določeno nezaupanje zaradi kompleksne sestave molekul, zahtevnejše analitike proizvajalca in potencialne imunogenosti.

Poleg tega je spremenjena cenovna politika in po eni strani tako večja razpoložljivost tako podobnih kot referenčnih bioloških zdravila vplivala na obseg dela v bolnišničnih lekarnah. Ker so se hkrati z uvajanjem in kliničnimi izkušnjami širile tako indikacije kot rahljale omejitve predpisovanja s strani ZZSZ, je bilo opazno znatno povečanje števila bolnikov, ki se (predvsem kronično) zdravilo bolnišnično oz. v okviru enodnevnih obravnav.

Aplikacija (podobnih) bioloških zdravil je primarno intravenska ali subkutana. Pot aplikacije, tveganje za mikrobiološko kontaminacijo pri pripravi, cena in možnost racionalne uporabe zdravila so dejavniki, ki narekujejo centralizirano pripravo omenjenih zdravil. Farmacevti v bolnišničnih lekarnah smo bili tako postavljeni pred izziv, kako vsem bolnikom, ki ta zdravila prejema, omogočiti, da prejmejo farmacevtski pripravek, ki bo izdelan v skladu s sodobnimi standardi, bo na voljo v za bolnika ustreznem odmerku in v razumnem času, predvsem v okviru enodnevne bolnišnične obravnave.

Uvedba podobnih bioloških zdravil je izpostavila vlogo in osvetlila celosten vpogled bolnišničnega farmacevta na celoten postopek uporabe zdravila, od postopka preskrbe in svetovanja ob uporabi v bolnišničnem okolju do racionalizacije in optimizacije priprave in aplikacije zdravila oziroma farmacevtskega pripravka.

Abstract

The introduction of biosimilar drugs into clinical practice has led to significant changes in the hospital environment. In the early stages, there was a noticeable lack of confidence among prescribers due to the complex composition of the molecules, the more sophisticated analytics required by manufacturers and the potential for immunogenicity.

In addition, changing pricing policies and the increased availability of both biosimilars and reference biological drugs have affected the workload in hospital pharmacies. With the expansion of indications and the easing of prescribing restrictions by our health insurance


institute, as well as the clinical experience gained, the number of patients receiving (mainly chronic) treatments in hospitals or as part of same-day procedures increased significantly.

The administration of (biosimilar) biological drugs is mainly intravenous or subcutaneous. The route of administration, the risk of microbiological contamination during preparation, the cost and the potential for rational use of the drug are factors that make centralized preparation of these drugs necessary. Thus, pharmacists in hospital pharmacies are faced with the challenge of ensuring that all patients receiving these drugs receive a pharmaceutical preparation that is prepared to modern standards, in a dosage appropriate to the patient and within a reasonable time, particularly in the context of same-day hospital care.


The introduction of biosimilars has highlighted the role and comprehensive insight of hospital pharmacists in the entire drug utilization process, from procurement procedures and hospital consultation to streamlining and optimizing drug preparation and administration.



1



2



3

Finančni vidik

- ZZZS
 - Vzdržnost javnih financ
 - Ohranjanje obsega „košarice“
 - Širjenje naroba bolnikov
- Javni razpisi
 - Izbira enega ponudnika
 - Izbira več ponudnikov
 - Tveganje pri stabilnosti preskrbe

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

4

Bolnikov vidik

- Hospitalna uporaba
 - Manj izrazita časovna komponenta
 - Kompleksnejši bolniki
- Ambulantna uporaba
 - Časovna komponenta
 - Manj kompleksni bolniki

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

5

Priprava farmacevtskih pripravkov

- Breckenridgevo poročilo (1976)
 - Letter: Addition of drugs to intravenous fluids
- Dejavniki tveganja
 - Pot aplikacije
 - Mikrobiološka kontaminacija
 - Cena/racionalna uporaba

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

6

Ocena tveganja

- Tradicionalen pristop
 - Priprava v istih prostorih kot citostatiki/zdravju škodljiva zdravila
- Praktičen/sodoben pristop
 - Ločeni prostori
 - Navzkrižna kontaminacija
- Konjugirana protitelesa

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

7

Racionalizacija dela

- Tradicionalen pristop
 - Priprava sproti za vsakega bolnika posebej sproti
- Praktičen/sodoben pristop
 - Priprava na „zalogo“
 - „Dose banding“
- Literaturni podatki o stabilnosti

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

8

Dodane vrednosti podobnih bioloških zdravil

- Stabilnostne študije proizvajalca
 - Objava podatkov
- Študije kompatibilnosti
 - Racionalizacija dela

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

9

Tveganja uporabe podobnih bioloških zdravil

- Širina izbora
 - Nabor bolnikov in obseg porabe
- Sledljivost
 - Sledenje po serijski številki

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024 10

10

Informacijska podpora

- Želje
 - Zaprta zanka
 - Uporaba bralnikov kod
- Realnost
 - Ročni vnosi
 - Odsotnost e-terapijskih listov
 - Pomanjkljivi nacionalni podatki
 - Nepovezani sistemi

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024 11

11

Povzetek

- Celosten pristop
- Povečanje kompleksnosti dela
- Zahteva po boljši informacijski podpori
- Boljši dostop do podatkov
- Nuja po racionalizaciji

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024 12

12

Vloga medicinske sestre pri implementaciji podobnih bioloških zdravil

The role of the nurse in the implementation of biosimilars

Boštjan Jovan

Univerzitetni klinični center Ljubljana, Klinični oddelek za hematologijo

Povzetek

Medicinske sestre igrajo ključno vlogo pri uspešni implementaciji PBZ, saj se soočajo s skepticizmom bolnikov, pomanjkanjem informacij in pomanjkljivim izobraževanjem. Njihovo znanje, izkušnje in sposobnosti pri izobraževanju bolnikov so nepogrešljive pri zagotavljanju varnosti in učinkovitosti zdravljenja. Zdravstvene institucije morajo zagotoviti ustrezno usposabljanje in podporo za medicinske sestre, da bodo lahko učinkovito izvajale svoje naloge. Poleg tega se morajo nenehno izobraževati o novih produktih, saj je razvoj novih produktov in njihov prihod na trg zelo velik.

Prve informacije o zdravljenju bolniku poda zdravnik, medicinske sestre so pogosto tiste, ki bolnikom nudijo podrobne informacije o zdravljenju, kar lahko vključuje razlago mehanizma delovanja PBZ, njihovih koristih in potencialnih neželenih učinkih, saj bolniki v bolnišnicah farmacevta praviloma niti ne vidijo. MS pridobijo bolnikovo soglasje, uvedejo vensko kanilo, po kateri bo zdravilo aplicirano, aplicirajo premedikacijo, PBZ, in skrbijo za opazovanje njegovega zdravstvenega stanja in pravočasne ukrepe ob nastanku neželenih reakcij. Za razliko od zdravnikov in farmacevtov MS velikokrat izpadejo iz procesa izobraževanja, saj slovenska zakonodaja omogoča informiranje predpisovalcev in farmacevtov o zdravilih in omejuje izobraževanje medicinskih sester. Izobražena medicinska sestra je ključna že pri pridobitvi soglasja (ustnega ali pisnega) za aplikacijo zdravila, za kar potrebuje visok nivo znanja tako o zdravilu, kot njegovih neželenih učinkih. Neželene učinke mora najprej prepoznati in nato na njih pravilno ukrepati. V kolikor bo bolnik utrpel katerega od neželenih učinkov in bodo ukrepi premišljeni in suvereni se bo bolnik počutil varno kljub nastalim težavam in bo pomirjen ob nadaljevanju zdravljenja. V nasprotnem primeru se lahko bolnik ustraši in ne želi nadaljevati s predvidenim zdravljenjem, kar ima lahko usodne posledice za njegovo zdravje.

Vloga MS pri implementaciji PBZ je zelo pomembna in le dobro educirana MS bo lahko podala relevantne informacije bolniku, primerno skrbela za njegovo zdravstveno stanje, zdravljenje glede na bolnikove potrebe individualno prilagodila ter v sodelovanju z ostalim multidisciplinarnim timom bolnikom omogočila optimalno zdravljenje.

Abstract

Nurses play a crucial role in the successful introduction of biosimilars (BSM) as they are confronted with patient skepticism, lack of information and insufficient training. Their knowledge, experience and patient education skills are critical to the safety and efficacy of the

treatment. Healthcare facilities must provide adequate training and support to nurses so that they can perform their duties effectively. In addition, nurses need to be constantly informed about new products, as the development of new products and their market launch are of great importance.


The first information about the treatment is given to the patient by the doctor, but it is often the nurses who provide detailed information about the treatment, e.g. the mechanism of action of BSM, its benefits and possible side effects, as patients do not usually visit pharmacists in the hospital. The nurse obtains the patient's consent, connects the intravenous cannula through which the drug is administered, administers the premedication and BSM, monitors the patient's health status and takes timely action in case of side effects.

Unlike doctors and pharmacists, nurses often fall outside the training process, as Slovenian legislation allows prescribers and pharmacists to be trained in medicines, but restricts the training of nurses. A well-trained nurse is crucial when it comes to obtaining consent (verbal or written) to administer medication, which requires a high level of knowledge about both the drug and its possible side effects. They must first recognize adverse effects and then respond appropriately. If a patient experiences adverse effects, careful and confident action on the part of the nurse will help the patient to feel safe despite the problems that arise and to continue treatment with peace of mind. If, on the other hand, the patient feels frightened and hesitates to continue the prescribed treatment, this can have serious consequences for their health.


The role of nurses in the implementation of BSM is very important. Only well-trained nurses are able to provide patients with relevant information, take appropriate care of their health condition, individualize treatment to the patient's needs and work with the multidisciplinary team to provide optimal treatment for patients.




1



2



3




Ključne naloge medicinskih sester

- **Izobraževanje bolnikov**
- Odgovarjanje na morebitna vprašanja
- Odpravljanje skrbi in dvomov
- Opozorilo o potencialnih neželenih učinkih
- Fizična priprava na zdravilo

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

4




Ključne naloge medicinskih sester

- **Spremljanje in ocenjevanje bolnikovega stanja**
- Merjenja vitalnih funkcij na določen časovni interval
- Stalno spremljanje bolnikovega zdravstvenega stanja
- Pozornost na spremembe
- Hitra odzivnost ob pojavu neželenih učinkov
- Natančno spremljanje in beleženje učinkov zdravljenja
- Poročanje ob pojavu neželenih učinkov

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

5




Multidisciplinarno sodelovanje


- Zdravniki
- Farmacevti
- Drugimi zdravstvenimi delavci v diagnostično terapevtskem procesu
- Oblikovanje enotnih kliničnih poti
- Deljenje informacij in izkušenj s sodelavci v domači ter v drugih ustanovah

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024


6



7



8



9

Zakonodaja

- 149 člen ZZdr-2
- Imetnik dovoljenja za promet z zdravilom mora voditi seznam strokovnih sodelavcev, ki:
- Oglašujejo zdravila
- So pooblašene za predpisovanje in izdajanje zdravil
- Kje so MS???

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

10

Zakonodaja

- 149 člen ZZdr-2
- Imetniki dovoljenja za promet z zdravilom, proizvajalci zdravil, poslovni subjekti, ki nastopajo v imenu proizvajalcev in tistih, ki opravljajo promet z zdravili, ter podružnice tujih proizvajalcev zdravil **lahko** omogočajo osebam, ki **predpisujejo in izdajajo zdravila** ter **osebam iz drugega odstavka** tega člena pridobivanje dodatnih znanj o novih zdravilih na znanstvenih in strokovnih srečanjih, vendar le v skladu z omejitvami iz šestega in sedmega odstavka tega člena.

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

11

Priprava zdravil farmacevt / MS

- Vrsta in količina topila
- Volumen nosilne tekočine
- Posebnosti pri pripravi
- Stabilnost po rekonstituciji
- Tveganja za lastno zdravje
 - Priprava
 - Aplikacija
 - Delo z bolnikom

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

12

Izzivi za medicinske sestre

Apliciranje zdravila

Prva infuzija

Priporočena začetna hitrost infundiranja je 50 mg/h; po prvih 30 minutah jo lahko vsakih 30 minut povečujemo po 50 mg/h, dokler ne dosežemo največje hitrosti infundiranja 400 mg/h.

in je pripravljen na ukrepanje v primeru anafilaksije.

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

13

Izzivi za medicinske sestre

Naslednje informacije so namenjene samo zdravstvenemu osebju:

oprema za ukrepanje v nujnih primerih.

Uporabite le iglo številka 21 ali večjo (0,8 mm ali manjši zunanji premer igle).

odstranjevanje levkocitov, s hitrostjo infundiranja približno 10 do 20 ml na minuto s težnostnim pretokom. Infundirati je treba celotno vsebino vseh infuzijskih vrečk. Za vzpostavljanje pretoka v

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

14

Izzivi za medicinske sestre

Omrežni podatki:

- Indikacije
- Odmerjanje
- Kontraindikacije
- Poslovna opozorila
- Interakcije
- Nosečnost
- Spodobnost vožnje
- Nabdelni učinki
- Preveliko odmerjanje
- Farmakodinamika
- Farmakokinetika

<https://medistatly.ca/si/drugs>

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

15

Izzivi za medicinske sestre

- Navodila za uporabo



<https://medicina.bhc.si/aktualno/obstajajo-se-spremembe-navodil-za-uporabo-zdravil/a/278640>

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

16


Izzivi za medicinske sestre

- Čas potreben od aplikacije premedikacije do zdravila?
- Spremljanje vitalnih funkcij
 - Katere?
 - Kako pogosto/stalni monitoring?
 - Koliko časa po zaključku?
- So neželeni učinki enaki kot pri originatorju?

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

17

Izzivi za medicinske sestre



<https://n-katalog.bupa.gov.uk/catalog/brands/denol/82122600>

<https://www.kimedhealth.com/ve-time/>

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

18



Priporočila za prakso

- Spodbujati timsko delo in multidisciplinarno komunikacijo
- Razviti izobraževalne programe za medicinske sestre
- Omogočiti dostop do evropskih/svetovnih smernic
- V navodila dodati za MS pomembne podatke
- Poudariti klinično pomembne razlike z originatorjem

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

19

19



Zaključek

- Pomembna vloga medicinskih sester pri uspešni implementaciji PBZ
- Razviti izobraževalne programe za medicinske sestre
 - Velika količina PBZ
- Prispevek k varnosti in učinkovitosti zdravljenja

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

20

20



Viri

- Beck, K. L., et al. (2019). "The role of nurses in the management of biosimilars." *Nursing Management*, 50(4), 36-42.
- Cohen, H., et al. (2018). "Patient understanding of biosimilars: the role of nursing education." *Journal of Nursing Practice*, 18(2), 105-111.
- García-Alonso, C., et al. (2021). "Monitoring biosimilar therapy: A nursing perspective." *Clinical Nursing Studies*, 9(3), 45-52.
- Hawkes, J. S., et al. (2018). "Multidisciplinary collaboration in biosimilar implementation." *Biosimilars Journal*, 7(1), 17-24.
- Kirk, R. M., et al. (2020). "Ethical considerations in the use of biosimilars." *Nursing Ethics*, 27(2), 430-439.
- Schneider, C. K., et al. (2017). "Biosimilars: what nurses need to know." *Journal of Nursing*, 34(5), 43-49.
- JAZMP
- Navodila za uporabo različnih proizvajalcev

17. mednarodni simpozij / 17th International Symposium, Ljubljana, 5. november 2024

21

21



22

Ali bomo v prihodnosti imeli na voljo podobna biološka zdravila?

Will we have biosimilars in the future? The biosimilar Void

Aurelio Arias

IQVIA

Povzetek

Čeprav je konkurenca biološko podobnih zdravil v Evropi igrala ključno vlogo pri doseganju znatnih prihrankov v zdravstvu in širšem dostopu pacientov do ključnih zdravil, spreminjajoča se narava prihodnjih iztekov patentne zaščite pomeni, da konkurenca in s tem povezani prihranki niso vedno zagotovljeni.

V tem prispevku predstavljamo aktualno analizo dejavnikov, ki vplivajo na spreminjajočo se raven aktivnosti na področju bioloških zdravil v Evropi, s poudarkom na razredih bioloških zdravil, pri katerih obstaja tveganje za zelo omejeno uvedbo biološko podobnih zdravil. Gre za koncept, imenovan "praznina biološko podobnih zdravil."


To bi lahko imelo širok spekter negativnih posledic za prihodnjo komercialno privlačnost sektorja biološko podobnih zdravil, prihranke za zdravstveni sistem in dostop pacientov do zdravil.

Abstract


While biosimilar competition in Europe has played a vital role in achieving significant healthcare savings and expanding patient access to key medicines, the changing nature of future loss of exclusivity (LoE) events means that competition, and by extension savings, is not always guaranteed.

In this session, we provide a timely analysis of the factors underlying the changing level of biologic pipeline activity in Europe, highlighting classes of biologics that are at risk of having very little biosimilar launches for them, a concept called "the biosimilar void."


This could have wide ranging negative implications on the future commercial attractiveness of the biosimilar sector, savings for the healthcare system and access to medicines for patients.




0




1




2




3




4




5



6



7



8



Full report available here:



Thank you

Aurelio Arias
Director, EMEA Thought Leadership, IQVIA

Vzdržnost zdravstvenega sistema in uspešna implementacija podobnih bioloških zdravil v Sloveniji: Kako doseči oboje?

How to make biosimilars a sustainable success in Slovenia

Jurij Fürst

Zavod za zdravstveno zavarovanje Slovenije

Povzetek


Pravila obveznega zdravstvenega zavarovanja (OZZ) določajo, da zdravnik izbere med zdravili v isti farmakološki skupini zdravilo z najboljšo stroškovno učinkovitostjo, med zdravili z enako učinkovino pa najcenejše na slovenskem trgu dostopno zdravilo. Uporabo dražjih paralel je torej treba utemeljiti s kliničnim stanjem bolnika, pri katerem cenejša paralela iz kliničnih razlogov ne more biti uporabljena. S prihodom generikov in podobnih bioloških zdravil, za katera Zavod doseže ob razvrstitvi na seznama A in B bistveno nižje cene, imajo bolnišnice in drugi izvajalci na voljo paralele z različnimi cenami. Ustrezno izveden javni razpis zato omogoči velike prihranke Zavodu in s tem olajša razvrščanje novih zdravil. Žal se pogosto dogaja, da se nove, cenejše paralele ne uporabljajo v takšnem obsegu, kot bi se lahko. ZZZS skuša osveščati strokovna združenja za čim večjo uporabo cenejših paralel, bolnišnice pa za pripravo preglednih, dobro zastavljenih javnih razpisov za zdravila.

Abstract


The rules of the Health Insurance Fund (ZZZS) stipulate that the doctor chooses the most cost-effective medicine among medicines in the same pharmacological group, and the cheapest medicine available on the Slovenian market among medicines with the same active ingredient. The use of more expensive parallels must therefore be justified by the clinical condition of the patient for whom the cheaper parallel cannot be used for clinical reasons. With new generics and biosimilars classified in Schedules A and B with significantly lower prices, hospitals and other providers have access to parallels with different prices. A properly executed tender therefore allows for significant savings for the ZZZS and thus facilitates the reimbursement of new medicines. Unfortunately, it is often the case that new, cheaper parallels are not used as much as they could be. The Health Insurance Fund is trying to raise awareness among professional associations to use cheaper parallels as much as possible and among hospitals to prepare transparent, well-designed tenders for medicines.




1



2



3




4


Izdatki OZZ za P listo ter seznam A in B

Seznam/Izdatki OZZ	1-12-2018	1-12-2019	1-12-2020	1-12-2021	1-12-2022	1-12-2023
Zdravila in živila na recept	333.852.646	336.995.221	368.571.079	412.303.096	459.618.449	520.784.020
Zdravila s seznamom B	89.989.073	98.749.406	130.638.197	141.198.621	144.714.675	163.734.929
Zdravila s seznamom A	20.233.192	19.829.530	19.326.236	18.542.669	26.334.803	27.349.674
SKUPAJ (ZDA TKI)	444.074.912	455.574.666	538.535.502	572.634.386	630.667.827	711.868.530
Povračila farmacevtskih družb	13.385.171	19.912.144	28.100.845	59.452.959	62.732.127	79.663.204
ZDA TKI - neto	430.689.740	435.662.522	510.434.656	513.181.427	567.935.700	632.205.327
Razlika na prejšnjo leto		4.972.782	74.772.734	2.746.821	54.754.223	64.269.627
Indeks neto izdatki OZZ		101,2	117,2	100,5	110,7	111,3
Indeks ip		100,9	115,1	106,3	111,3	113,3
Indeks seznam B		109,7	132,2	108,1	102,5	113,1
Indeks seznam A		98,0	97,5	95,9	142,0	109,5
Indeks povračila		148,8	141,1	211,6	105,5	127,0


5




6



7



8



9
